

Game changing session 1

Game changing session

Friday 17 July
08:30 - 09:10

Location: Virtual room 1

Chairs: A. Briganti, Milan (IT)
M. Wirth, Dresden (DE)

08:30 - 08:50

Contenance following robot-assisted (R-LRPE) and conventional laparoscopic radical prostatectomy (LRPE) – results of a prospective, randomized, multicenter, patient blinded study

08:30 - 08:37

Pre-recorded
lecture

Presenter

J-U. Stolzenburg, Leipzig (DE)

08:37 - 08:45

Pre-recorded
lecture

Discussant

A. De La Taille, Créteil (FR)

08:45 - 08:50

Live

Discussion, questions and answers

A. Briganti, Milan (IT)
M. Wirth, Dresden (DE)

08:50 - 09:10

ProPSMA Study: A prospective randomised multi-centre study of PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy

08:50 - 08:57

Pre-recorded
lecture

Presenter

M. Hofman, Melbourne (AU)

08:57 - 09:05

Pre-recorded
lecture

Discussant

M. Heck, Munich (DE)

09:05 - 09:10

Live

Discussion, questions and answers

A. Briganti, Milan (IT)
M. Wirth, Dresden (DE)

Modern prostate cancer imaging in daily practice

Plenary session 01

Friday 17 July
09:10 - 11:40

Location: Virtual room 2

Chairs: J. Walz, Marseille (FR)
H.P.A.M. Van Poppel, Leuven (BE)

Learning Objectives of this session

Imaging of prostate cancer is a rapidly changing field with many new technologies being established in the last few years. Actually true paradigm shifts were observed as image guided diagnosis of prostate cancer became a standard of care at last year's EAU meeting. However, these new clinical pathways generate also problems and fields of uncertainty such as how to put them into context with modern biomarkers, how to apply these new pathways in the community setting, and how to make clinical benefit out of modern molecular imaging? This session addresses the most pertinent problems and issue encountered with modern imaging and gives answers how those might be overcome.

09:10 - 09:20	Pre-recorded lecture	Ultrasound in prostate cancer imaging: Dead or ready to get started? C.K. Mannaerts, Amsterdam (NL)
09:20 - 10:10		Prostate biopsies
09:20 - 09:30	Pre-recorded lecture	Imaging as triage H.U. Ahmed, London (GB)
09:30 - 09:40	Pre-recorded lecture	What might genomics add to the decision? G. Jenster, Rotterdam (NL)
09:40 - 09:50	Pre-recorded lecture	MRI in the expert center vs. MRI in the community center C. Kastner, Cambridge (GB)
09:50 - 10:00	Pre-recorded lecture	Risk stratification of prostate cancer based on targeted biopsies B.A. Hadaschik, Essen (DE)
10:00 - 10:10	Pre-recorded lecture	What should you do with men you do not biopsy, or whose biopsy is negative? A. Lamb, Oxford (GB)
10:10 - 10:20	Pre-recorded lecture	Screening strategy and active surveillance in 2020 C.H. Bangma, Rotterdam (NL)
10:20 - 10:45		Biochemical recurrence I
10:20 - 10:25	Pre-recorded lecture	Biochemical recurrence after radical prostatectomy A. Herlemann, Munich (DE)
10:25 - 10:35	Pre-recorded lecture	Let's ask for imaging B. Tombal, Brussels (BE)
10:35 - 10:45	Pre-recorded lecture	Let's start with early treatment P. Nyirády, Budapest (HU)
10:45 - 11:20		Biochemical recurrence II

10:45 - 10:52	Pre-recorded lecture	The biochemical recurrence patient L. Moris, Leuven (BE)
10:52 - 10:59	Pre-recorded lecture	Systemic treatment G. Ploussard, Toulouse (FR)
10:59 - 11:06	Pre-recorded lecture	Metastasis-directed therapy with radiotherapy P. Ost, Ghent (BE)
11:06 - 11:13	Pre-recorded lecture	Metastases-directed therapy with surgery T. Maurer, Hamburg (DE)
11:13 - 11:20	Pre-recorded lecture	Summary from the EAU Prostate Cancer Guidelines Panel N. Mottet, Saint-Étienne (FR)
<hr/>		
11:20 - 11:30	Pre-recorded lecture	A peek into the future: Artificial intelligence and prostate cancer imaging O. Rouvière, Lyon (FR)
<hr/>		
11:30 - 11:40	Live	Discussion, questions and answers
<hr/>		
11:30 - 11:40		J. Walz, Marseille (FR)
11:30 - 11:40		H.P.A.M. Van Poppel, Leuven (BE)

Focal therapy for prostate cancer: Mid-term oncological outcomes and salvage radical prostatectomy

Thematic session 01

Friday 17 July
11:40 - 13:00

Location: Virtual room 1

Chairs: C.H. Bangma, Rotterdam (NL)
A. Villers, Lille (FR)

Learning Objectives of this session

This session on focal therapy for intermediate-risk prostate cancer addresses the oncological outcomes with at least 3 years of followup. Various energies will be reported and discussed with the panel.

In case of focal therapy failure, salvage radical prostatectomy is a treatment option. However, it may be technically challenging, and pathology may show adverse features. The session participants will be able to make a decision when and how to advise the individual patient with intermediate risk cancer considering focal therapy and what to expect in case of salvage radical prostatectomy.

11:40 - 11:45

Live

Introduction to focal therapy

A. Villers, Lille (FR)

11:45 - 12:25

Midterm oncological results of focal therapy

11:45 - 11:50

Pre-recorded
lecture

IRE focal ablation

P.D. Stricker, Sydney (AU)

11:50 - 11:55

Pre-recorded
lecture

HIFU focal ablation

C. Orczyk, London (GB)

11:55 - 12:00

Pre-recorded
lecture

HIFU hemi-ablation

J. Olivier, Lille (FR)

12:00 - 12:05

Pre-recorded
lecture

Cryotherapy focal ablation

H.U. Ahmed, London (GB)

12:05 - 12:10

Pre-recorded
lecture

VTP TOOKAD

A. Borkowetz, Dresden (DE)

12:10 - 12:25

Live

Panel discussion

Moderators: C.H. Bangma, Rotterdam (NL)
A. Villers, Lille (FR)

Panel: H.U. Ahmed, London (GB)
A. Borkowetz, Dresden (DE)
J. Olivier, Lille (FR)
C. Orczyk, London (GB)
P.D. Stricker, Sydney (AU)

12:25 - 12:45

Outcomes of salvage radical prostatectomy after focal therapy

12:25 - 12:35

Pre-recorded
lecture

Good functional and pathological results

S. Crouzet, Lyon (FR)

12:35 - 12:45

Pre-recorded
lecture

Disappointing functional and pathological results

P. Sooriakumaran, London (GB)

12:45 - 13:00 **Live** Discussion, questions and answers

12:45 - 13:00 C.H. Bangma, Rotterdam (NL)

12:45 - 13:00 A. Villers, Lille (FR)

New frontiers in infections

Plenary Session 02

Friday 17 July
13:00 - 14:30

Location: Virtual room 2

Chairs: J.P.F.A. Heesakkers, Nijmegen (NL)
F.M.E. Wagenlehner, Giessen (DE)

Learning Objectives of this session

Urological infections become more and more difficult to treat, due to the fact that on the one hand antimicrobial resistance and multiresistance emerge dramatically in causative pathogens on a global level and antibiotics are increasingly restricted. On the other hand urological patients do have more and more accompanying morbidities. This session deals with the most important and recent aspects and strategies that deal with the challenges of antimicrobial resistance, from prevention and prophylaxis to treatment of life threatening infections.

13:00 - 13:15

Pre-recorded
lecture

View on the Coronavirus crisis from an European perspective

M.J.M. Bonten, Utrecht (NL)

13:15 - 13:30

Pre-recorded
lecture

New diagnostic techniques to overcome antibiotic resistance

S. Halachmi, Haifa (IL)

13:30 - 13:50

How to minimise infectious complications of prostate biopsies: A white paper

13:30 - 13:35

Pre-recorded
lecture

Case presentation

J.P.M. Sedelaar, Nijmegen (NL)

13:35 - 13:50

Pre-recorded
lecture

State-of-the-art lecture

A. Pilatz, Giessen (DE)

13:50 - 14:05

Pre-recorded
lecture

Urosepsis: Hot data from the SERPENS study

Z. Tandoğdu, London (GB)

14:05 - 14:25

Infection control practices in patients at risk for multiresistant pathogens

14:05 - 14:15

Pre-recorded
lecture

Pro isolation

S.J. Harbarth, Genève (CH)

14:15 - 14:25

Pre-recorded
lecture

Against isolation

G. Bonkat, Basel (CH)

14:25 - 14:30

Live

Discussion, questions and answers

14:25 - 14:30

J.P.F.A. Heesakkers, Nijmegen (NL)

14:25 - 14:30

F.M.E. Wagenlehner, Giessen (DE)

Men's health 2020

Thematic session 02

Friday 17 July
15:30 - 17:00**Location:** Virtual room 2**Chairs:** C. Gratzke, Freiburg (DE)
J.O.R. Sønksen, Herlev (DK)**Learning Objectives of this session**

In this thematic session, we will highlight the role of the urologist as the gatekeeper for men's health. Indeed, many symptom complexes (such as LUTS and ED) that we face as urologists are sentinels of systemic and potentially life-threatening diseases. Also men with infertility have been identified as having a poorer general health status compared to their fertile counterparts. In the first part of this session, top-level speakers will highlight how to recognize and deal with these underlying comorbidities in our patients. The second part of the session will focus on maximally maintaining quality of life in its most diverse facets when dealing with a man with prostatic disease, in which the urologist again bears the responsibility to serve as a gatekeeper of men's health and quality of life.

15:30 - 16:00**The urologist as a gatekeeper for men's health****15:30 - 15:40**Pre-recorded
lecture**LUTS**

M. Gacci, Florence (IT)

15:40 - 15:50Pre-recorded
lecture**Erectile dysfunction**

A. Parnham, Manchester (GB)

15:50 - 16:00Pre-recorded
lecture**Male infertility**

L. Boeri, Milan (IT)

16:00 - 16:55**Case-based debate** **Preservation of quality of life in prostatic disease****16:00 - 16:05**Pre-recorded
lecture**Case presentation**

A. Mattigk, Ulm (DE)

16:05 - 16:15Pre-recorded
lecture**Alpha blockers and 5-ARI: Effects on libido and ejaculation**

G.I. Russo, Catania (IT)

16:15 - 16:25Pre-recorded
lecture**Daily PDE5 inhibitors**

M. Oelke, Gronau (DE)

16:25 - 16:35Pre-recorded
lecture**TRT will ameliorate all his symptoms**

G. Corona, Bologna (IT)

16:35 - 16:45Pre-recorded
lecture**Ejaculation preserving surgical options: Pro**

L. De Kort, Utrecht (NL)

16:45 - 16:55Pre-recorded
lecture**Ejaculation preserving surgical options: Con**

T. Hermanns, Zürich (CH)

16:55 - 17:00

Live

Discussion, questions and answers**16:55 - 17:00**

C. Gratzke, Freiburg (DE)

16:55 - 17:00

J.O.R. Sønksen, Herlev (DK)

Management of patients with CRPC in 2020

Thematic session 03

Friday 17 July
17:00 - 18:30

Location: Virtual room 1

Chairs: M. De Santis, Berlin (DE)
M. Wirth, Dresden (DE)

Learning Objectives of this session

This session will review the current challenges in the management of castration resistant prostate cancer in view of novel imaging, novel therapeutics, earlier use of anticancer drugs, molecular markers and pathology. A focus will be prediction of response and sequencing of treatment options. Case based discussions will exemplify the challenges in 2020 for daily practice.

17:00 - 17:15	Pre-recorded lecture	CRPC: Prediction of response to systemic treatment L. Horvath, Sydney (AU)
17:15 - 17:30	Pre-recorded lecture	Imaging of CRPC - what is possible, what is necessary? W.L. Loidl, Linz (AT)
17:30 - 17:45	Pre-recorded lecture	Molecular pathology before systemic treatment - what is feasible? S. Perner, Luebeck (DE)
17:45 - 18:10		Case-based debate M0 CRPC: Androgen Receptor Targeted Treatment (ARTA)
17:45 - 17:50	Pre-recorded lecture	Case presentation G. Gandaglia, Milan (IT)
17:50 - 18:00	Pre-recorded lecture	Yes A. Morgans, Chicago (US)
18:00 - 18:10	Pre-recorded lecture	No J. Bedke, Tübingen (DE)
18:10 - 18:20	Pre-recorded lecture	The best sequence for M+ CRPC in 2020 A. Birtle, Preston (GB)
18:20 - 18:30	Live	Discussion, questions and answers
18:20 - 18:30		M. De Santis, Berlin (DE)
18:20 - 18:30		M. Wirth, Dresden (DE)

Radioligand therapy in metastatic castration-resistant prostate cancer

Thematic session 04

Friday 17 July
18:30 - 20:00

Location: Virtual room 2

Chairs: A. Briganti, Milan (IT)
M. Heck, Munich (DE)
D. Murphy, Melbourne (AU)

Learning Objectives of this session

Prostate-specific membrane antigen (PSMA) offers great potential not only as a target for diagnostic but also for therapeutic purposes. The present session highlights the application of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Indication, limitations and future developments will be discussed.

18:30 - 18:45	Pre-recorded lecture	Current and future radioligands (ligands and emitters) M. Gauthé, Paris (FR)
18:45 - 19:00	Pre-recorded lecture	Limitations of PSMA based on prostate cancer biology P. Rescigno, London (GB)
19:00 - 19:15	Pre-recorded lecture	Critical assessment of radioligand therapy T. Steuber, Hamburg (DE)
19:15 - 19:50		Case-based debate (PSMA)-targeted radioligand therapy: For which patients, which stages?
19:15 - 19:20	Pre-recorded lecture	Case presentation I. Tsaour, Mainz (DE)
19:20 - 19:30	Pre-recorded lecture	Treatment options: Medical oncologist U. Vogl, Bellinzona (CH)
19:30 - 19:40	Pre-recorded lecture	Treatment options: Nuclear medicine M. Eiber, Munich (DE)
19:40 - 19:50	Pre-recorded lecture	Radioligand therapy for less advanced cases: Urologist A. Heidenreich, Cologne (DE)
19:50 - 20:00	Live	Discussion, questions and answers
19:50 - 20:00		A. Briganti, Milan (IT)
19:50 - 20:00		M. Heck, Munich (DE)
19:50 - 20:00		D. Murphy, Melbourne (AU)

Game changing session 2

Game changing session

Saturday 18 July 08:30 - 09:05		Location: Virtual room 1
		Chairs: J. Palou, Barcelona (ES) K. Tikkinen, Helsinki (FI)
08:30 - 08:45		Recurrence risk in patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial 'NIMBUS' stratified for EORTC and CUETO risk categories. A contemporary trend to less recurrences?
08:30 - 08:37	Pre-recorded lecture	Presenter M-O. Grimm, Jena (DE)
08:37 - 08:45	Pre-recorded lecture	Discussant P. Black, Vancouver (CA)
08:45 - 09:00		Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients (pts) with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
08:45 - 08:52	Pre-recorded lecture	Presenter N. Shore, Myrtle Beach (US)
08:52 - 09:00	Pre-recorded lecture	Discussant J.A. Witjes, Nijmegen (NL)
09:00 - 09:05	Live	Discussion, questions and answers
09:00 - 09:05		J. Palou, Barcelona (ES)
09:00 - 09:05		K. Tikkinen, Helsinki (FI)

Challenges across the spectrum of bladder cancer

Plenary session 03

Saturday 18 July
09:05 - 11:25

Location: Virtual room 2

Chairs: J.W.F. Catto, Sheffield (GB)
M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)

Learning Objectives of this session

Clinical decision making for non muscle-invasive bladder cancer and new tools for adjuvant treatment for these tumours take a large part of this session. Furthermore an optimisation in the selection of elderly patients with advanced bladder cancer for surgical vs. conservative treatment will be presented. One part of the session deals with personalised treatment and its underlying genetic testing in bladder cancer.

09:05 - 09:15

Pre-recorded
lecture

Definition of very high-risk and refractory NMIBC

M. Babjuk, Prague (CZ)

09:15 - 09:45

Early cystectomy in high-risk NMIBC: A standard?

09:15 - 09:25

Pre-recorded
lecture

Pro

S. Shariat, Vienna (AT)

09:25 - 09:35

Pre-recorded
lecture

Con

J. Palou, Barcelona (ES)

09:35 - 09:45

Live

Discussion

Moderators: J.W.F. Catto, Sheffield (GB)
M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)

Panel: J. Palou, Barcelona (ES)
S. Shariat, Vienna (AT)

09:45 - 10:00

Pre-recorded
lecture

Immunotherapy and beyond: New options for NMIBC

P. Black, Vancouver (CA)

10:00 - 10:15

Pre-recorded
lecture

Urinary markers in low-grade NMIBC: Ready to stop cystoscopies?

J.A. Witjes, Nijmegen (NL)

10:15 - 10:30

Pre-recorded
lecture

Frailty and cognitive assessment in patients diagnosed with MIBC

G. Pignot, Marseille (FR)

10:30 - 10:45

Pre-recorded
lecture

Treatment options for elderly patients with muscle-invasive bladder cancer

M.J. Ribal Caparros, Barcelona (ES)

10:45 - 11:00

Pre-recorded
lecture

Different bladder cancer genotypes: New treatment options

R. Seiler, Bern (CH)

11:00 - 11:15

Pre-recorded
lecture

The future of personalised treatment: Test the tumour for a response

M. Shen, New York (US)

11:15 - 11:25

Live

Discussion, questions and answers

11:15 - 11:25	J.W.F. Catto, Sheffield (GB)
11:15 - 11:25	M. Rouprêt, Paris (FR)
11:15 - 11:25	A. Stenzl, Tübingen (DE)

Five things I wish I would have known earlier in my career: Lessons from the mentors

Thematic session 05

Saturday 18 July
11:25 - 13:00

Location: Virtual room 1

Chairs: F. Montorsi, Milan (IT)
J. Palou, Barcelona (ES)

Learning Objectives of this session

During a long and successful career, many decisions that are taken on the basis of the evidence available at that specific time have subsequently proven incorrect.

Three recognised Mentors in Urology: Peter Carroll for Prostate Cancer, Inderbir Gill for Kidney Cancer and Mark Soloway for Bladder Cancer will scrutinize their own extraordinary personal experience achieved over many years to identify the mistakes done, how they were able to manage them and how they subsequently changed their practice.

At the end of each talk, another top expert in the same field will summarize for the audience what the contemporary guidelines are saying about the management of that disease.

Delegates will learn from the outstanding experience of these giants in urology and their counterparts. Learning from mistakes is a phenomenally important part of the professional growth of each urologist.

11:25 - 11:55

Bladder cancer

11:25 - 11:45

Pre-recorded
lecture

Speaker

M.S. Soloway, Miami (US)

11:45 - 11:55

Pre-recorded
lecture

Discussant

J.W.F. Catto, Sheffield (GB)

11:55 - 12:25

Kidney cancer

11:55 - 12:15

Pre-recorded
lecture

Speaker

I.S. Gill, Los Angeles (US)

12:15 - 12:25

Pre-recorded
lecture

Discussant

C.K. Bensalah, Rennes (FR)

12:25 - 12:55

Prostate cancer

12:25 - 12:45

Pre-recorded
lecture

Speaker

P. Carroll, San Francisco (US)

12:45 - 12:55

Pre-recorded
lecture

Discussant

A. Briganti, Milan (IT)

12:55 - 13:00

Live

Discussion, questions and answers

12:55 - 13:00

F. Montorsi, Milan (IT)

12:55 - 13:00

J. Palou, Barcelona (ES)

Game changing session 3

Game changing session

Saturday 18 July 13:00 - 13:20		Location: Virtual room 2
		Chairs: C.R. Chapple, Sheffield (GB) H.P.A.M. Van Poppel, Leuven (BE)
13:00 - 13:15		The real effect of prostate cancer treatment: EUPROMS study first patient driven quality of life study ever
13:00 - 13:08	Pre-recorded lecture	Presenter A. Deschamps, Antwerpen (BE)
13:08 - 13:15	Pre-recorded lecture	Discussant S. Joniau, Leuven (BE)
13:15 - 13:20	Live	Discussion, questions and answers
13:15 - 13:20		C.R. Chapple, Sheffield (GB)
13:15 - 13:20		H.P.A.M. Van Poppel, Leuven (BE)

Bladder dysfunction, storage symptoms and benign prostatic disease

Plenary session 04

Saturday 18 July
13:20 - 15:00

Location: Virtual room 1

Chairs: J-N.L. Cornu, Rouen (FR)
C. Gratzke, Freiburg (DE)

Learning Objectives of this session

This plenary session on male LUTS will cover the topic of bladder dysfunction especially in the context of concomitant benign prostatic obstruction. Leaders in the field will comprehensively discuss up-to-date medical and surgical solutions, recent advances in the therapies of male LUTS and current key pathophysiological concepts underlying male LUTS.

13:20 - 13:30	Pre-recorded lecture	Basic neurological workup in a male LUTS patient: Keypoints for daily clinical practice L. Campeau, Montreal (CA)
13:30 - 13:55		Non-neurogenic OAB in a 60yr man with 60g prostate: First-line medical prescription
13:30 - 13:35	Pre-recorded lecture	Choose anticholinergics C. De Nunzio, Rome (IT)
13:35 - 13:40	Pre-recorded lecture	Choose a Beta-3 agonist J-N.L. Cornu, Rouen (FR)
13:40 - 13:45	Pre-recorded lecture	Choose alpha blockers S.A. Arlandis, Valencia (ES)
13:45 - 13:50	Pre-recorded lecture	Role of combination therapy S. Madersbacher, Vienna (AT)
13:50 - 13:55	Live	Questions and answers J-N.L. Cornu, Rouen (FR) C. Gratzke, Freiburg (DE)
13:55 - 14:20		Non-neurogenic OAB and proven obstruction, drugs don't work
13:55 - 14:00	Pre-recorded lecture	Preference for resection M. Speakman, Taunton (GB)
14:00 - 14:05	Pre-recorded lecture	Preference for vaporisation M. Gacci, Florence (IT)
14:05 - 14:10	Pre-recorded lecture	Preference for enucleation T.R.W. Herrmann, Frauenfeld (CH)
14:10 - 14:15	Pre-recorded lecture	Preference for aquablation A. Miernik, Freiburg (DE)
14:15 - 14:20	Live	Questions and answers J-N.L. Cornu, Rouen (FR) C. Gratzke, Freiburg (DE)

14:20 - 14:30	Pre-recorded lecture	Persistence of OAB symptoms after prostate surgery, despite good de-obstruction M. Rieken, Vienna (AT)
<hr/>		
14:30 - 15:00		Minimally-invasive options for day case surgery
<hr/>		
14:30 - 14:35	Pre-recorded lecture	Urolift N. Barber, Camberley (GB)
14:35 - 14:40	Pre-recorded lecture	TIND F. Porpiglia, Turin (IT)
14:40 - 14:45	Pre-recorded lecture	Rezum therapy R.G. Hindley, Hook (GB)
14:45 - 14:50	Pre-recorded lecture	Day case Greenlight laser vaporisation B. Pradere, Toulouse (FR)
14:50 - 14:55	Pre-recorded lecture	Prostate embolisation D. Abt, St. Gallen (CH)
<hr/>		
14:55 - 15:00	Live	Questions and answers J-N.L. Cornu, Rouen (FR) C. Gratzke, Freiburg (DE)

Urinary reconstruction in (neuro)urology

Thematic session 06

Saturday 18 July
16:00 - 16:30

Location: Virtual room 1

Chairs: C.R. Chapple, Sheffield (GB)
J.P.F.A. Heesakkers, Nijmegen (NL)

Learning Objectives of this session

After the introduction of botulinum toxin A in the armamentarium of neurogenic bladder dysfunction, other more complex treatment options have been very much ignored. However Botulinum toxin does not work in every case. Advances in sacral neuromodulation have occurred and may prove useful for neurogenic patients. Urinary diversion may be a realistic option in complex cases, and urologists need to familiarize themselves with other neurological problems in addition to MS or SCI. Parkinson's disease is a good example of a disease with multiple urological problems urologists that should be aware of.

16:00 - 16:30

Debate What happens if Botox does not work in MS anymore?

16:00 - 16:05

Pre-recorded
lecture

Case presentation

M. Tutolo, Milan (IT)

16:05 - 16:15

Pre-recorded
lecture

Go for surgery

G. Karsenty, Marseille (FR)

16:15 - 16:25

Pre-recorded
lecture

Stay conservative

G. Del Popolo, Florence (IT)

16:25 - 16:30

Live

Discussion, questions and answers

C.R. Chapple, Sheffield (GB)

J.P.F.A. Heesakkers, Nijmegen (NL)

Best abstract session: Non-oncology

Poster Session

Saturday 18 July 16:30 - 17:00		Location: Virtual room 2
		Chairs: C. Gratzke, Freiburg (DE) J.O.R. Sønksen, Herlev (DK)
16:30 - 16:40		3rd prize - non-oncology 640 Increased stromal components and prostatic fibrosis via altering the CYP19/Estrogen/GPER signaling in the early progression of BPH tissues of men ≤ 50 years old
16:30 - 16:35	Pre-recorded lecture	Presenter Y. Yang, Beijing (CN)
16:35 - 16:40	Pre-recorded lecture	Discussant K. Tikkinen, Helsinki (FI)
16:40 - 16:50		2nd prize - non-oncology 285 Are glomerulations still a characteristic marker for interstitial cystitis/bladder pain syndrome? Biological evidences from global gene expression and comprehensive immunohistochemical quantification analysesv
16:40 - 16:45	Pre-recorded lecture	Presenter Y. Akiyama, Tokyo (JP)
16:45 - 16:50	Pre-recorded lecture	Discussant J.P.F.A. Heesakkers, Nijmegen (NL)
16:50 - 17:00		1st prize - non-oncology 423 Novel model of micturition based on a multi-unit recordings of optogenetically-identified Barrington's CRH neurons in mice
16:50 - 16:55	Pre-recorded lecture	Presenter H. Ito, Kawasaki-City (JP)
16:55 - 17:00	Pre-recorded lecture	Discussant J-N.L. Cornu, Rouen (FR)

Immunotherapy and beyond

Thematic session 07

Saturday 18 July
17:00 - 18:10

Location: Virtual room 1

Chairs: S. Gillessen Sommer, Bellinzona (CH)
R.J. Van Soest, Rotterdam (NL)

Learning Objectives of this session

This session will provide an overview of the current challenges and obstacles in the treatment of urothelial cancer and renal cell carcinoma in view of recently approved agents and combinations including immunotherapy, targeted agents and combinations.

17:00 - 17:20

Perioperative therapy for urothelial cancer

17:00 - 17:10

Pre-recorded
lecture

PD-1/PD-L1 Inhibitors are replacing perioperative chemotherapy

J.L. Boormans, Rotterdam (NL)

17:10 - 17:20

Pre-recorded
lecture

Chemotherapy remains standard of care

G. Niegisch, Düsseldorf (DE)

17:20 - 17:30

Pre-recorded
lecture

Should we sequence all urothelial cancer patients?

S. Shariat, Vienna (AT)

17:30 - 17:50

Immunotherapy combinations for intermediate-poor risk mRCC

17:30 - 17:40

Pre-recorded
lecture

IO + TKI

A.S. Merseburger, Lübeck (DE)

17:40 - 17:50

Pre-recorded
lecture

IO + IO

M. Schmidinger, Vienna (AT)

17:50 - 18:00

Pre-recorded
lecture

Novel urothelial cancer treatment beyond PD-1/PD-L1 inhibition

Y. Loriot, Villejuif (FR)

18:00 - 18:10

Live

Discussion, questions and answers

18:00 - 18:10

S. Gillessen Sommer, Bellinzona (CH)

18:00 - 18:10

R.J. Van Soest, Rotterdam (NL)

Salvage LND prostate cancer

Thematic session 08

Saturday 18 July
18:10 - 19:40

Location: Virtual room 2

Chairs: C.H. Bangma, Rotterdam (NL)
F. Montorsi, Milan (IT)

Learning Objectives of this session

Here we review the biology and treatment for advanced local and distant metastatic prostate cancer. We consider treatment options and discuss which is better and for whom.

18:10 - 18:25 Pre-recorded lecture **Does early diagnosis help the patient?**
A. Briganti, Milan (IT)

18:25 - 19:00 **Primary treatment of pelvic lymph node metastatic prostate cancer**

18:25 - 18:35 Pre-recorded lecture **Surgery only**
K. Touijer, New York (US)

18:35 - 18:45 Pre-recorded lecture **Radiation only**
N. Van As, London (GB)

18:45 - 18:55 Pre-recorded lecture **Systemic only**
R.J.A. Van Moorselaar, Amsterdam (NL)

18:55 - 19:00 Live **Discussion, questions and answers**
C.H. Bangma, Rotterdam (NL)
F. Montorsi, Milan (IT)

19:00 - 19:25 **Treatment of recurrent lymph node metastatic PCa**

19:00 - 19:10 Pre-recorded lecture **Surgery is the best option**
S. Joniau, Leuven (BE)

19:10 - 19:20 Pre-recorded lecture **Radiation is the best option**
A. Bossi, Villejuif (FR)

19:20 - 19:25 Live **Discussion, questions and answers**
C.H. Bangma, Rotterdam (NL)
F. Montorsi, Milan (IT)

19:25 - 19:40 Pre-recorded lecture **Treatment of polymetastatic hormone sensitive prostate cancer**
C. Sweeney, Boston (US)

Best abstract session: Oncology

Poster Session

Saturday 18 July 19:40 - 20:00		Location: Virtual room 1
		Chairs: P. Albers, Düsseldorf (DE) Z. Culig, Innsbruck (AT)
19:40 - 19:50		2nd prize - oncology 925 Late toxicity and quality of life from GETUG-AFU 22 study: A randomised phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy
19:40 - 19:45	Pre-recorded lecture	Presenter P. Sargos, Bordeaux (FR)
19:45 - 19:50	Pre-recorded lecture	Discussant A. Briganti, Milan (IT)
19:50 - 20:00		1st prize - oncology PT090 Inhibition steroid sulfatase suppresses androgen signaling and improves response to enzalutamide
19:50 - 19:55	Pre-recorded lecture	Presenter A. Gao, Sacramento (US)
19:55 - 20:00	Pre-recorded lecture	Discussant Z. Culig, Innsbruck (AT)

Game changing session 4

Game changing session

Sunday 19 July 08:30 - 09:05		Location: Virtual room 1
		Chairs: M-O. Grimm, Jena (DE) J. N'Dow, Aberdeen (GB)
08:30 - 08:45		A prospective randomized study of bicalutamide +/- docetaxel for non metastatic prostate cancer with a rising PSA (SPCG-14)
08:30 - 08:37	Pre-recorded lecture	Presenter A.S. Josefsson, Göteborg (SE)
08:37 - 08:45	Pre-recorded lecture	Discussant C. Sweeney, Boston (US)
08:45 - 09:00		Health-related quality-of-life (HRQoL) analysis from KEYNOTE-426: pembrolizumab (pembro) plus axitinib (axi) vs sunitinib for advanced renal cell carcinoma (RCC)
08:45 - 08:52	Pre-recorded lecture	Presenter J. Bedke, Tübingen (DE)
08:52 - 09:00	Pre-recorded lecture	Discussant I. Duran, Santander (ES)
09:00 - 09:05	Live	Discussion, questions and answers
09:00 - 09:05		M-O. Grimm, Jena (DE)
09:00 - 09:05		J. N'Dow, Aberdeen (GB)

Live session: Nightmare on robotics

Plenary session 05

Sunday 19 July
09:05 - 11:35

Location: Virtual room 2

Chairs: T.S. O'Brien, London (GB)
A. Mottrie, Aalst (BE)

Learning Objectives of this session

Bertie Leigh is back exploring and probing the complications of robotic surgery through the prism of the law court. In so doing we hope to improve approaches to consent, surgical technique and training.

Scenarios 1&3 explore challenges arising from the uniqueness of robotics viz, what to do after mechanical failure and issues arising from the physical separation of surgeon and assistant. Scenario 2 explores the transition to performing highly complex robotic procedures.

The session will be entertaining and challenging. "If my case came to court, how would I look?"

09:05 - 09:50

Mechanical failure of the robot during RARP: Should I have stopped?

09:05 - 09:10

Live

Case presentation

D. Tilki, Hamburg (DE)

09:10 - 09:20

Live

Case discussion

A. De La Taille, Créteil (FR)

09:20 - 09:40

Live

Cross-examination

B. Leigh, London (GB)

09:40 - 09:50

Live

Case solution

T.S. O'Brien, London (GB)

09:50 - 10:35

Were you ready for this level of complexity? Robotic T3 RCC into the IVC

09:50 - 09:55

Live

Case presentation

A. Larcher, Milan (IT)

09:55 - 10:05

Live

Case discussion

C. Schwentner, Stuttgart (DE)

10:05 - 10:25

Live

Cross-examination

B. Leigh, London (GB)

10:25 - 10:35

Live

Case solution

T.S. O'Brien, London (GB)

10:35 - 11:20

Was your team appropriately skilled? Bowel perforation during robotic radical cystectomy

10:35 - 10:40	Live	Case presentation R. Nair, London (GB)
10:40 - 10:50	Live	Case discussion C.J. Wijburg, Arnhem (NL)
10:50 - 11:10	Live	Cross-examination B. Leigh, London (GB)
11:10 - 11:20	Live	Case solution T.S. O'Brien, London (GB)

11:20 - 11:35	Live	Discussion, questions and answers
----------------------	------	--

11:20 - 11:35		T.S. O'Brien, London (GB)
11:20 - 11:35		A. Mottrie, Aalst (BE)

Complications of renal surgery

Thematic session 09

Sunday 19 July
11:35 - 13:00

Location: Virtual room 1

Chairs: A. Breda, Barcelona (ES)
J. Rassweiler, Heilbronn (DE)

Learning Objectives of this session

Based on the previous series of thematic sessions on complications, we want to focus this year on complications of renal surgery including all type of approaches from endourology to open surgery. European experts will present typical complications and their management. Discussion of the presented cases with the audience guided by the two moderators will be an important part of the session.

11:35 - 11:50	Pre-recorded lecture	Complications of laparoscopic renal surgery P.L. Chlosta, Cracow (PL)
11:50 - 12:05	Pre-recorded lecture	Complications of robotic renal surgery A. Minervini, Florence (IT)
12:05 - 12:20	Pre-recorded lecture	Complications of retrograde intra-renal surgery M. Fiedler, Heilbronn (DE)
12:20 - 12:35	Pre-recorded lecture	Complications of renal transplantation F.J. González Garcia, Madrid (ES)
12:35 - 12:50	Pre-recorded lecture	Complications of open renal surgery M.S. Michel, Mannheim (DE)
12:50 - 13:00	Live	Discussion, questions and answers
12:50 - 13:00		A. Breda, Barcelona (ES)
12:50 - 13:00		J. Rassweiler, Heilbronn (DE)

Stones: The role of innovation

Plenary session 06

Sunday 19 July 13:00 - 15:10		Location: Virtual room 2 Chairs: W.F.J. Feitz, Nijmegen (NL) T. Knoll, Sindelfingen (DE) K. Sarica, Istanbul (TR)
Learning Objectives of this session Today, stone treatment means endourology in most cases. New endoscopes, new lasers, new disposables promise better efficacy, lower morbidity and shorter hospital stays. Is this all true or are there potential drawbacks to be considered? Which protocols and treatment algorithms lead to the best treatment results? This plenary will give answers.		
13:00 - 13:10	Pre-recorded lecture	Temperature and intrarenal pressure during laser lithotripsy E. Liatsikos, Patras (GR)
13:10 - 13:35		Perioperative Antibiotic Prophylaxis: When, how and how long?
13:10 - 13:20	Pre-recorded lecture	When? E. Montanari, Milan (IT)
13:20 - 13:30	Pre-recorded lecture	How (long)? C.C. Seitz, Vienna (AT)
13:30 - 13:35	Live	Questions and answers W.F.J. Feitz, Nijmegen (NL) T. Knoll, Sindelfingen (DE) K. Sarica, Istanbul (TR)
13:35 - 13:45	Pre-recorded lecture	How to minimise radiation exposure in endourology A. Skolarikos, Athens (GR)
13:45 - 14:05		New technology in retrograde intrarenal surgery: Unnecessary luxury vs. measurable benefit
13:45 - 13:50	Pre-recorded lecture	Measurable benefit S. Proietti, Milan (IT)
13:50 - 13:55	Pre-recorded lecture	Unnecessary luxury A. Neisius, Trier (DE)
13:55 - 14:05	Pre-recorded lecture	Rebuttal A. Neisius, Trier (DE) S. Proietti, Milan (IT)
14:05 - 14:45		Beyond holmium laser: New lithotripsy devices
14:05 - 14:15	Pre-recorded lecture	Holmium K. Ghani, Ann Arbor (US)
14:15 - 14:25	Pre-recorded lecture	Thulium P.M. Kronenberg, Amadora (PT)
14:25 - 14:35	Pre-recorded lecture	Ballistic O. Wiseman, Cambridge (GB)

14:35 - 14:45	Live	Questions and answers W.F.J. Feitz, Nijmegen (NL) T. Knoll, Sindelfingen (DE) K. Sarica, Istanbul (TR)
14:45 - 15:10		1cm stone in the lower calyx plus 2cm upper ureteral stone with complete obstruction
14:45 - 14:50	Pre-recorded lecture	Retrograde ureteroscopy T. Tailly, Ghent (BE)
14:50 - 14:55	Pre-recorded lecture	Percutaneous nephrolithotomy and antegrade ureteroscopy N. Gadzhiev, Saint Petersburg (RU)
14:55 - 15:00	Pre-recorded lecture	Laparoscopic ureterolithotomy and flexible nephroscopy B. Resorlu, Ankara (TR)
15:00 - 15:10	Live	Questions and answers W.F.J. Feitz, Nijmegen (NL) T. Knoll, Sindelfingen (DE) K. Sarica, Istanbul (TR)

New technology for urology

Thematic session 10

Sunday 19 July
16:10 - 17:00

Location: Virtual room 2

Chairs: C.H. Bangma, Rotterdam (NL)
W.F.J. Feitz, Nijmegen (NL)
J. Rassweiler, Heilbronn (DE)

Learning Objectives of this session

Development in technologies are pivotal for progress in Urology. The session shows scientific areas that are interesting for a urologic research agenda throughout Europe, and triggers the mind of young urologists to seek for complementary training.

16:10 - 16:30

Patterns and computers

16:10 - 16:20

Pre-recorded
lecture

Recognising images, tissues, signals

W.J. Niessen, Rotterdam (NL)

16:20 - 16:30

Pre-recorded
lecture

Imagine all the people... is there a second, digital, me?

C. Auffray, Lyon (FR)

16:30 - 16:55

Small devices, new materials

16:30 - 16:40

Pre-recorded
lecture

Modulating urologic nerves

N.J.M. Rijkhoff, Aalborg (DK)

16:40 - 16:50

Pre-recorded
lecture

New technology for urology: 7T MRI scanner

W. Van der Zwaag, Amsterdam (NL)

16:50 - 16:55

Pre-recorded
lecture

What are the consequences for implants in urology with the new EU directive?

J.P.F.A. Heesakkers, Nijmegen (NL)

16:55 - 17:00

Live

Discussion, questions and answers

16:55 - 17:00

C.H. Bangma, Rotterdam (NL)

16:55 - 17:00

W.F.J. Feitz, Nijmegen (NL)

16:55 - 17:00

J. Rassweiler, Heilbronn (DE)

#Testis cancer and surgical andrology

Plenary session 07

Sunday 19 July
17:00 - 19:00**Location:** Virtual room 1**Chairs:** P. Albers, Düsseldorf (DE)
M. Albersen, Leuven (BE)
M.S. Silay, Istanbul (TR)**Learning Objectives of this session**

After starting off this session with an update on the treatment algorithm of Peyronie's disease and surgical aspects of genital reconstruction, the interrelationship of testicular cancer and male infertility –both arising from the testicular dysgenesis syndrome (TDS)- will be discussed. The attendee will take home a deeper insight in the molecular connection between these two diseases and the impact of one diagnosis on the management of the other. Autologous testicular tissue transplants are on the horizon and will be highlighted. MicroRNAs as biomarkers and robotic approaches of retroperitoneal masses are further topics of discussion and state-of-the art presentations will help to clarify their roles in current management.

17:00 - 17:10	Pre-recorded lecture	The current treatment algorithm for Peyronie's disease: Is there still a role for surgery? J.I. Martínez Salamanca, Majadahonda (ES)
17:10 - 17:25	Pre-recorded lecture	"I wish I'd never... ": Complications and how to avoid them in male genital reconstructions D.J. Ralph, London (GB)
17:25 - 17:35	Pre-recorded lecture	Infertility and the risk of testis cancer: New molecular connections L. Looijenga, Rotterdam (NL)
17:35 - 17:50	Pre-recorded lecture	Autologous testicular tissue transplantation in young cancer patients: How far are we? K. Orwig, Pittsburgh (US)
17:50 - 18:00	Pre-recorded lecture	How to manage testicular microlithiasis and CIS M. Dinkelman-Smit, Rotterdam (NL)
18:00 - 18:15	Pre-recorded lecture	The new testis cancer biomarker miRNA 371: Ready for prime time? R. Hamilton, Toronto (CA)
18:15 - 18:45		Twitter told me the robot can do it: Small retroperitoneal masses in testis cancer, what is best? Stage IIA
18:15 - 18:20	Pre-recorded lecture	Case presentation J.L. Vásquez, Roskilde (DK)
18:20 - 18:30	Pre-recorded lecture	Open RPLND is still the gold standard D. Nicol, London (GB)
18:30 - 18:40	Pre-recorded lecture	Robotic RPLND is safe and feasible A. Hiester, Düsseldorf (DE)
18:40 - 18:45	Pre-recorded lecture	Concluding remarks and rebuttal: Was Twitter right? Can we use SoMe to better educate patients? J.L. Vásquez, Roskilde (DK)

18:45 - 19:00

Live

Discussion, questions and answers

18:45 - 19:00

P. Albers, Düsseldorf (DE)

18:45 - 19:00

M. Albersen, Leuven (BE)

18:45 - 19:00

M.S. Silay, Istanbul (TR)

Controversies in renal cancer surgery

Thematic session 11

Sunday 19 July
19:00 - 20:00

Location: Virtual room 2

Chairs: M-O. Grimm, Jena (DE)
A. Minervini, Florence (IT)

Learning Objectives of this session

In renal cancer surgery a number of new controversies have emerged during recent years. The paradigm of organ preservation “whenever possible” has been challenged by doubts about its benefit depending on comorbid disease. Another controversy concerns the surgical approach to partial nephrectomy, open vs. minimally invasive. Finally, cytoreductive nephrectomy is not any more the standard in synchronous metastatic RCC if VEGFR-TKI therapy is intended. But what is the evidence with modern PD-1/PD-L1 immune-checkpoint inhibitor based combination therapies?

These and other surgical “hot topics” will be discussed – join the session and take part!

19:00 - 19:20

Case based debate Organ preservation: Do the benefits outweigh additional risks?

19:00 - 19:05

Pre-recorded lecture

Case presentation

M-O. Grimm, Jena (DE)

19:05 - 19:10

Pre-recorded lecture

Pro: Partial nephrectomy

A. Breda, Barcelona (ES)

19:10 - 19:15

Pre-recorded lecture

Pro: Minimally invasive nephrectomy

M. Tran, London (GB)

19:15 - 19:20

Live

Discussion, questions and answers

M-O. Grimm, Jena (DE)

A. Minervini, Florence (IT)

19:20 - 19:30

Pre-recorded lecture

Open vs. minimally invasive partial nephrectomy: What is the evidence?

M.C. Mir Maresma, Barcelona (ES)

19:30 - 19:40

Pre-recorded lecture

How to best approach the large renal mass: Tips and tricks

T.S. O'Brien, London (GB)

19:40 - 20:00

Case based debate Cytoreductive nephrectomy: What do we know?

19:40 - 19:45

Pre-recorded lecture

Case presentation

M-O. Grimm, Jena (DE)

19:45 - 19:50

Pre-recorded lecture

Cytoreductive nephrectomy may be an option only after response

A. Bex, London (GB)

19:50 - 19:55

Pre-recorded lecture

Pro: Upfront cytoreductive nephrectomy

A. Finelli, Toronto (CA)

19:55 - 20:00

Live

Discussion, questions and answers

M-O. Grimm, Jena (DE)

A. Minervini, Florence (IT)

Andrology and genital cancers: Novelties surrounding that other Corona

Poster Session 1

Monday 20 July
18:00 - 18:45

Location: Virtual room 1

Chairs: M. Albersen, Leuven (BE)
M.M. Fode, Herlev (DK)
A. Muneer, London (GB)

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

18:00 - 18:04

Pre-recorded
lecture

13 The response of prostate cancer cell lines to exogenous testosterone: Lessons for clinical practice

By: Birch B.R.P., Hald O.

University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

18:04 - 18:08

Pre-recorded
lecture

315 Assessing the impact of male cancers on total motile sperm count

By: Smith M. ¹, Tharakan T. ², Stroud T. ¹, Goh E.T. ³, Figueiredo M. ³, Joannou L. ³, Dearing C. ⁴, Vyas L. ², Jayasena C. ³, Ramsay J. ³, Minhas S. ²

¹Imperial College London, School of Medicine, London, United Kingdom, ²Imperial College Healthcare Trust, Dept. of Urology, London, United Kingdom, ³Imperial College Healthcare Trust, Dept. of Andrology, London, United Kingdom, ⁴Eastern Institute of Technology, School of Health Science and Nursing, Taradale, New Zealand

18:08 - 18:12

Pre-recorded
lecture

320 Challenging the guidelines: Proposal of a new sperm concentration cut-off for Y chromosome microdeletions testing in primary infertile men

By: Cazzaniga W. ¹, Capogrosso P. ¹, Boeri L. ², Ventimiglia E. ¹, Pozzi E. ¹, Baudo A. ¹, Candela L. ¹, Pellegrino F. ¹, Oreggia D. ¹, Abbate C. ¹, Mirone V. ³, Montorsi F. ¹, Salonia A. ¹

¹IRCCS Ospedale San Raffaele, Unit of Urology; URI, Milan, Italy, ²IRCCS Fondazione Ca' Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, ³Naples University, Dept. of Urology, Naples, Italy

18:12 - 18:16

Pre-recorded
lecture

609 Cytotoxic T-lymphocytes and dendritic cells driving the inflammatory micro-environment of Peyronie's disease

By: Milenkovic U. ¹, Boeckx B. ², Lambrechts D. ², Van Renterghem K. ³, Bivalacqua T.J. ⁴, De Ridder D. ¹, Albersen M. ¹

¹KU Leuven, Dept. of Development and Regeneration, Laboratory of Experimental Urology, Leuven, Belgium, ²VIB-KU Leuven, Dept. of Laboratory of Translational Genetics, Leuven, Belgium, ³Jessa Hospital, Dept. of Urology, Hasselt, Belgium, ⁴Johns Hopkins Medical Institute, Dept. of Urology, Baltimore, United States of America

18:16 - 18:20

Pre-recorded
lecture

494 Can low intensity shockwaves therapy compete the efficacy of PDE5is? A pooled data analysis from 2 randomized clinical trials

By: Mykoniatis I., Kalyvianakis D., Kapoteli P., Zilotis F., Fournaraki A., Hatzichristou D. Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece

18:20 - 18:24

Pre-recorded
lecture**487 Effect of antimicrobial dipping solutions on post-operative infection rates in diabetic patients undergoing primary insertion of a Coloplast titan inflatable penile prosthesis**

By: Towe M. ¹, Osman M.M. ¹, Huynh L.M. ¹, El-Khatib F.M. ¹, Andrianne R. ², Broderick G. ³, Burnett A. ⁴, Clavell-Hernandez J. ⁵, Gross M. ⁶, Guise A.I. ⁷, Hatzichristodoulou G. ⁸, Henry G.D. ⁹, Hsieh T. ¹⁰, Jenkins L.C. ¹¹, Lentz A. ¹², Munarriz R.M. ¹³, Osmonov D. ¹⁴, Sung Hun P. ¹⁵, Perito P. ¹⁶, Sadeghi-Nejad H. ¹⁷, Simhan J. ¹⁸, Wang R. ⁵, Yafi F.A. ¹

¹UC Irvine Health, Dept. of Urology, Orange, United States of America, ²Centre Hospitalier Universitaire de Liège, Dept. of Urology, Liège, Belgium, ³Mayo Clinic, Dept. of Urology, Jacksonville, United States of America, ⁴The Johns Hopkins Hospital, Dept. of Urology, Baltimore, United States of America, ⁵University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁶Dartmouth-Hitchcock Medical Center, Dept. of Urology, Lebanon, United States of America, ⁷Medical College of Wisconsin, Dept. of Urology, Milwaukee, United States of America, ⁸Julius-Maximilians-University of Würzburg, Dept. of Urology, Würzburg, Germany, ⁹ArkLaTex Urology, Dept. of Urology, Bossier City, United States of America, ¹⁰UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ¹¹Ohio State University, Dept. of Urology, Columbus, United States of America, ¹²Duke University Medical Center, Dept. of Urology, Durham, United States of America, ¹³Boston University Medical Center, Dept. of Urology, Boston, United States of America, ¹⁴Christian Albrechts University of Kiel, Dept. of Urology, Kiel, Germany, ¹⁵Sewum Prosthetic Urology Center of Excellence, Dept. of Urology, Seoul, South Korea, ¹⁶Perito Urology, Dept. of Urology, Coral Gables, United States of America, ¹⁷Hackensack University Medical Center, Dept. of Urology, Hackensack, United States of America, ¹⁸Einstein Healthcare Network, Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America

18:24 - 18:28

Pre-recorded
lecture**216 Location and histology of retroperitoneal metastases in post-chemotherapy retroperitoneal lymph node dissection for non-seminoma germ cell tumour**

By: Gerdtsen A. ¹, Thor A. ², Grenabo A. ³, Almås B. ⁴, Negaard H.F.S. ⁵, Glimelius I. ⁶, Halvorsen D. ⁷, Karlsdóttir Á. ⁸, Haugnes H.S. ⁹, Andreassen K.E. ⁵, Larsen S.M. ¹⁰, Holmberg G. ³, Wahlqvist R. ¹⁰, Tandstad T. ¹¹, Cohn-Cedermark G. ¹², Ståhl O. ¹³, Kjellman A. ²

¹Dept of Urology, CLINTEC, Karolinska Institutet, Stockholm, Sweden, Dept. of Urology, Malmö, Sweden, ²CLINTEC, Dept. of Urology, Stockholm, Sweden, ³Gothenburg University, Dept. of Urology, Gothenburg, Sweden, ⁴Haukeland University hospital, Dept. of Urology, Bergen, Norway, ⁵Oslo University Hospital, Dept. of Oncology, Oslo, Norway, ⁶Uppsala University, Immunology, Genetics and Pathology, Unit of clinical and experimental oncology, Uppsala, Sweden, ⁷St. Olavs University Hospital, Dept. of Urology, Trondheim, Norway, ⁸Haukeland University Hospital, Dept. of Oncology, Bergen, Norway, ⁹University Hospital of North Norway, Clinical Medicine, UIT- The Arctic University of Norway, Tromsø, Sweden, ¹⁰Oslo University Hospital, Dept. of Urology, Oslo, Norway, ¹¹St. Olavs University Hospital, Dept. of clinical and molecular medicine, Trondheim, Norway, ¹²Karolinska institutet, Oncology-Pathology, Stockholm, Sweden, ¹³Skåne University Hospital, Dept. of Oncology, Lund, Sweden

18:28 - 18:32

Pre-recorded
lecture**217 Minimally invasive retroperitoneal lymph node dissection (MI-RPLND) and single dose adjuvant carboplatin for low volume stage 2 seminoma – 3 year outcomes**By: Nicol D.¹, Huddart R.¹, Reid A.², Hazell S.³, Sohaib A.⁴, Mayer E.⁵

¹Royal Marsden Hospital, Institute of Cancer Research, Dept. of Urology, London, United Kingdom, ²Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ³Royal Marsden Hospital, Dept. of Pathology, London, United Kingdom, ⁴Royal Marsden Hospital, Dept. of Radiology, London, United Kingdom, ⁵Royal Marsden Hospital, Imperial College, Dept. of Urology, London, United Kingdom

18:32 - 18:36

Pre-recorded
lecture**143 Establishment, characterization and imaging of a first platinum-resistant penile cancer patient derived xenograft in nude mice: An eUROGEN project**By: Albersen M.¹, Vanthoor J.¹, Thomas A.², Milenkovic U.¹, Dumez H.³, De Meerleer G.⁴, Joniau S.¹, Everaerts W.¹, Tsaour I.², Muneer A.⁵, Himmelreich U.⁶, Cawthorne C.⁶, Deroose C. M.⁷, Spans L.⁸, Vanden Bempt I.⁸, Leucci E.⁹, Van Rompuy A.¹⁰, Rizzotto L.⁹

¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Medicine Mainz, Dept. of Urology, Mainz, Germany, ³University Hospitals Leuven, Dept. of Medical Oncology, Leuven, Belgium, ⁴University Hospitals Leuven, Dept. of Radiation Oncology, Leuven, Belgium, ⁵University College London Hospital, NIHR Biomedical Research Centre, London, United Kingdom, ⁶KU Leuven, Biomedical MRI/Molecular Small Animal Imaging Center (MoSAIC), Leuven, Belgium, ⁷University Hospitals Leuven, Dept. of Nuclear Medicine & Molecular Imaging, Leuven, Belgium, ⁸KU Leuven, Dept. of Human Genetics, Leuven, Belgium, ⁹KU Leuven, Trace - PDTX Platform Dept. of Oncology, Laboratory of RNA Cancer Biology, Leuven, Belgium, ¹⁰University Hospitals Leuven, Dept. of Pathology, Leuven, Belgium

18:36 - 18:40

Pre-recorded
lecture**144 Validation of hybrid ICG-99mTc-nanocolloid for sentinel node biopsy in a large cohort of penile cancer patients: Improved sentinel node detection compared to blue dye**By: Dell'Oglio P.¹, De Vries H.M.², Mazzone E.³, Horenblas S.², Van Der Poel H.G.², Van Leeuwen F.W.B.⁴, Brouwer O.R.²

¹The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital; Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ²The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ³San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁴Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands

Challenges in andrology

Video Session 1

Monday 20 July
19:45 - 20:15

Location: Virtual room 1

Chairs: F. Cancrini, Rome (IT)
E. Kocjancic, Chicago (US)
I. Moncada Iribarren, Madrid (ES)

All videos have a maximum length of 8 minutes, followed by 4 minutes of live discussion.

19:45 - 19:54

V090 Post-infiltration ultrasound evaluation of collagenase clostridium histolyticum for the treatment of Peyronie's disease: Independent factor of therapeutic success

By: Cocci A.¹, Russo G.I.², Cito G.¹, Romano A.¹, Verrienti P.¹, Cai T.³, Bartoletti R.⁴, Morelli G.⁴, Minervini A.¹, Polloni G.⁵, Rizzo M.³, Falcone M.⁶, Mondaini N.⁷

¹University of Florence, Dept. of Urology, Florence, Italy, ²University of Catania, Dept. of Urology, Catania, Italy, ³University of Trieste, Dept. of Urology, Trieste, Italy, ⁴University of Pisa, Dept. of Urology, Pisa, Italy, ⁵Psychosexuology, Psychosexuology, Como, Italy, ⁶University of Turin, Hospital Molinette, Dept. of Urology, Turin, Italy, ⁷Villa Donatello Hospital, Uro- Andrology, Florence, Italy

19:54 - 20:06

V091 New technique for penile prosthesis implantation in severely fibrosed corpora cavernosa; the "un-folding technique"

By: Abdel-Rassoul M.A.

Cairo University, Dept. of Urology, Cairo, Egypt

New frontiers in urological imaging

Poster Session 2

Tuesday 21 July
18:00 - 18:45

Location: Virtual room 1

Chairs: G. Salomon, Hamburg (DE)
R. Sanchez-Salas, Paris (FR)
N.R. Suardi, Genoa (IT)

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

18:00 - 18:04

Pre-recorded
lecture

353 A new quality control scoring system for multiparametric MRI of the prostate from the PRECISION trial

By: Giganti F.¹, Kasivisvanathan V.², Punwani S.¹, Emberton M.², Allen C.¹, Moore C.M.²

¹University College London Hospital, Dept. of Radiology, London, United Kingdom,

²University College London Hospital, Dept. of Urology, London, United Kingdom

18:04 - 18:08

Pre-recorded
lecture

270 Which prostate cancers are overlooked by mpMRI? An analysis from PROMIS

By: Norris J.¹, Carmona Echeverria L.¹, Bott S.R.J.², Brown L.³, Burns-Cox N.⁴, Dudderidge T.J.⁵, El-Shater Bosaily A.¹, Frangou E.³, Freeman A.⁶, Ghei M.⁷, Henderson A.⁸, Hindley R.G.⁹, Kaplan R.S.³, Kirkham A.¹⁰, Oldroyd R.¹¹, Parker C.¹², Persad R.¹³, Punwani S.¹, Rosario D.J.¹⁴, Shergill I.S.¹⁵, Stavrinides V.¹, Winkler M.¹⁶, Whitaker H.C.¹, Ahmed H.U.¹⁶, Emberton M.¹

¹University College London, UCL Division of Surgery & Interventional Science, London, United Kingdom, ²Frimley Health NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³University College London, Medical Research Council (MRC) Clinical Trials Unit, London, United Kingdom, ⁴Taunton & Somerset NHS Foundation Trust, Dept. of Urology, Taunton, United Kingdom, ⁵University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ⁶University College London Hospitals NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁷Whittington Health NHS Trust, Dept. of Urology, London, United Kingdom, ⁸Maidstone & Tunbridge Wells NHS Trust, Dept. of Urology, Tunbridge Wells, United Kingdom, ⁹Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke, United Kingdom, ¹⁰University College London Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ¹¹Public & Patient Representative, Public & Patient Representative, Nottingham, United Kingdom, ¹²The Royal Marsden NHS Foundation Trust, Dept. of Academic Urology, London, United Kingdom, ¹³North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, ¹⁴Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom, ¹⁵Wrexham Maelor Hospital NHS Trust, Dept. of Urology, Wrexham, United Kingdom, ¹⁶Imperial College London, Dept. of Surgery & Cancer, London, United Kingdom

18:08 - 18:12

Pre-recorded
lecture**1031 Does inclusion of MRI in active surveillance decrease the rate of discontinuation? A reflection of the use of MRI in the PRIAS study**By: Luiting H.B.¹, Remmers S.¹, Boevé E.R.², Zollo F.³, Badenchini F.³, Rannikko A.⁴, Roobol M.¹¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands,²Franciscus Gasthuis & Vlietland, Dept. of Urology, Rotterdam, The Netherlands,³Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Tumori, Dept. ofUrology, Milano, Italy, ⁴Helsinki University Hospital and University of Helsinki, Dept. of Urology, Helsinki, Finland

18:12 - 18:16

Pre-recorded
lecture**1147 Prospective evaluation of pelvic lymph node staging with 18fluorine prostate-specific membrane antigen PET/CT prior to extended lymph node dissection in primary prostate cancer – the SALT trial**By: Jansen B.H.E.¹, Bodar Y.J.L.¹, Zwezerijnen G.J.C.², Nieuwenhuijzen J.A.¹, Wondergem M.³, Roeleveld T.⁴, Hoektra O.S.², Van Moorselaar J.¹, Oprea-Lager D.E.², Vis A.N.¹¹Amsterdam UMC, location VUmc, Dept. of Urology, Amsterdam, The Netherlands,²Amsterdam UMC, location VUmc, Dept. of Nuclear Medicine, Amsterdam, TheNetherlands, ³Noordwest Ziekenhuisgroep, Dept. of Nuclear Medicine, Alkmaar, TheNetherlands, ⁴Noordwest Ziekenhuisgroep, Dept. of Urology, Alkmaar, The Netherlands

18:16 - 18:20

Pre-recorded
lecture**800 Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial**By: Ferdinandus J.¹, Fendler W.P.¹, Calais J.², Eiber M.³, Flavell R.R.⁴, Mishoe A.⁴, Feng F.Y.⁵, Nguyen H.G.⁶, Reiter R.E.⁵, Rettig M.B.⁷, Gartmann J.⁸, Smith R.⁴, Small E.J.⁶, Slavik R.², Carroll P.R.⁵, Herrmann K.¹, Czernin J.², Hope T.A.⁴¹University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany, ²University ofCalifornia Los Angeles, Ahmanson Translational Imaging Division, Dept. of Molecular and Medical Pharmacology, Los Angeles, United States of America, ³Klinikum rechts der Isar,Dept. Nuclear Medicine, Munich, Germany, ⁴University of California San Francisco, Dept. of Radiology and Biomedical Imaging and Pharmaceutical Chemistry, San Francisco,United States of America, ⁵University of California San Francisco, Dept. of Urology, SanFrancisco, United States of America, ⁶University of California San Francisco, Helen DillerFamily Comprehensive Cancer Center, San Francisco, United States of America, ⁷UCLA

Medical Center, University of California Los Angeles, Dept. of Urology, Los Angeles,

United States of America, ⁸University of California Los Angeles, Ahmanson Translational

Imaging Division, Department of Molecular and Medical Pharmacology, Los Angeles,

United States of America

18:20 - 18:24

Pre-recorded
lecture**529 No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study**By: Bandini M.¹, Zaffuto E.¹, Scuderi S.¹, Pederzoli F.¹, Marandino L.², Raggi D.², Barletta F.¹, Gandaglia G.¹, Fossati N.¹, Burgio G.¹, Moschini M.³, Zamboni S.³, Afferi L.³, Comara S.¹, Briganti A.¹, Montorsi F.¹, Colombo R.¹, Necchi A.², Gallina A.¹¹Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Fondazione IRCCSIstituto Nazionale dei Tumori, Dept. of Oncology, Milan, Italy, ³Klinik für Urologie, Luzerner

Kantonsspital, Dept. of Urology, Lucerne, Switzerland

18:24 - 18:28

Pre-recorded
lecture**530 Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath trial**

By: Bryan R.T.¹, Pirrie S.J.¹, Liu W.¹, Amir R.², Gallagher J.³, Hughes A.I.¹, Jefferson K.P.⁴, Knight A.⁵, Nanton V.⁶, Mintz H.P.⁶, Pope A.M.⁷, Catto J.W.F.⁸, Patel P.¹, James N.D.¹

¹University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, ²University Hospitals Birmingham NHS Foundation Trust, Dept. of Radiology, Birmingham, United Kingdom, ³Patient Advocate, Bingley, United Kingdom, ⁴University Hospitals Coventry and Warwickshire NHS Trust, Dept. of Urology, Coventry, United Kingdom, ⁵Action Bladder Cancer UK, Chairman and Patient Advocate, Tetbury, United Kingdom, ⁶University of Warwick, Warwick Medical School, Coventry, United Kingdom, ⁷University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, ⁸University of Sheffield, Dept. of Oncology and Metabolism, Sheffield, United Kingdom

18:28 - 18:32

Pre-recorded
lecture**535 Clinical impact of [18F] Fluorodeoxyglucose positron emission tomography/computed tomography on management of patients with muscle-invasive bladder cancer**

By: Voskuilen C.S.¹, Van Gennep E.J.¹, Vegt E.², Donswijk M.², Fransen Van De Putte E.E.¹, Van Der Poel H.G.¹, Horenblas S.¹, Van Rhijn B.W.G.¹, Hendricksen K.¹, Mertens L.S.¹

¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands

18:32 - 18:36

Pre-recorded
lecture**794 Combination of Dual Energy CT scan and Infrared Spectroscopy: Analysis of imaging accuracy in prediction of different stones composition and stiffness**

By: Capretti C.C.¹, Milanese G.¹, Cameli A.M.², Sbaraglia F.², Mari A.², Pierini L.², Misericordia M.², Scarcella S.¹, Giovagnoni A.², Giuseppetti G.M.², Galosi A.B.¹

¹Polytechnic University of Marche Region, Dept. of Urology, Ancona, Italy, ²Polytechnic University of Marche Region, Dept. of Radiology, Ancona, Italy

18:36 - 18:40

Pre-recorded
lecture**475 Utility of diffusion-weighted magnetic resonance imaging radiomics features in the differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma**

By: Matsumoto S.¹, Yoshida S.¹, Yamada I.², Kijima T.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Saito K.¹, Tateishi U.², Fujii Y.¹

¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Tokyo Medical and Dental University, Diagnostic Radiology and Nuclear Medicine, Tokyo, Japan

Clinical applications of novel imaging techniques

Video Session 2

**Tuesday 21 July
19:45 - 20:15****Location:** Virtual room 1**Chairs:** C.K. Bensalah, Rennes (FR)
A. Carbone, Latina (IT)
R.F. Van Velthoven, Brussels (BE)

All videos have a maximum length of 8 minutes, followed by 4 minutes of live discussion.

19:45 - 19:55**V072 Rapid segmentation of renal tumours to calculate volume using 3D interpolation**By: Chen M.Y-C.¹, Woodruff M.A.², Rukin N.J.¹¹Redcliffe Hospital, Dept. of Urology, Brisbane, Australia, ²Queensland University of Technology, Science and Engineering Faculty, Brisbane, Australia**19:55 - 20:06****V021 Contrast-enhanced trans-rectal ultrasound for surveillance of post-treatment recurrence after focal HIFU of prostate**By: Cacciamani G.E.¹, Shakir A.¹, Fujihara A.¹, Iwata T.¹, Tafuri A.¹, Palmer S.², Gill I.¹, Abreu A.L.¹¹University of Southern California, Dept. of Urology, Los Angeles, United States of America, ²University of Southern California, Dept. of Radiology, Los Angeles, United States of America

Surgical options in functional urology: Shaping the future

Poster Session 3

Wednesday 22
July
18:00 - 18:45

Location: Virtual room 1

Chairs: R. Bauer, Munich (DE)
N. Thiruchelvam, Cambridge (GB)
K. Tikkinen, Helsinki (FI)

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

18:00 - 18:04

Pre-recorded
lecture

201 Two-year outcomes after aquablation compared to TURP: Results from a blinded randomized trial

By: Barber N.¹, Gilling P.², Bidair M.³, Anderson P.⁴, Sutton M.A.⁵, Aho T.⁶, Thomas A.⁷, Te A.⁸, Roehrborn C.G.⁹

¹Frimley Health NHS Foundation Trust, Dept. of Urology, Surrey, United Kingdom, ²University of Auckland, Dept. of Urology, Tauranga, New Zealand, ³Alvarado Medical Institute, Dept. of Urology, San Diego, United States of America, ⁴The Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ⁵Houston Methodist Hospital, Dept. of Urology, Houston, United States of America, ⁶Adenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, ⁷Princess of Wales Hospital, Dept. of Urology, Bridgend, United Kingdom, ⁸New York Presbyterian Hospital, Dept. of Urology, New York, United States of America, ⁹UT Southwestern Medical Centre, Dept. of Urology, Dallas, United States of America

18:04 - 18:08

Pre-recorded
lecture

212 Five-year preliminary functional urinary outcomes of the prospective, randomized controlled trial of convective water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia

By: Roehrborn C.¹, McVary K.T.²

¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²Loyola University Medical Center, Dept. of Urology, Maywood IL, United States of America

18:08 - 18:12

Pre-recorded
lecture

650 Prostatic urethral lift real-world study confirms effectiveness and safety in a broad array of patient groups

By: Kayes O.

Leeds Teaching Hospitals, Dept. of Urology, Leeds, United Kingdom

18:12 - 18:16

Pre-recorded
lecture

831 A prospective, randomised clinical trial comparing holmium laser enucleation versus photoselective vaporization for day-surgery to treat benign prostatic hyperplasia

By: Chen Y.B., Chen Q., Gu M., Liu C., Wang Z.

Shanghai Ninth People's Hospital, Dept. of Urology, Shanghai, China

18:16 - 18:20	Pre-recorded lecture	<p>207 Second generation of temporary implantable nitinol device (iTind) in men with lower urinary tract symptoms (LUTS): Who profit most from treatment? 2 year results of the MT-02-study</p> <p>By: <u>Kadner G.</u>¹, Valerio M.², Giannakis I.¹, Arya M.³, Lumen N.⁴, Ho B.S.⁵, Alonso S.⁶, Schulman C.⁷, Barber N.⁸, Amparore D.⁹, Porpigila F.⁹</p> <p>¹Kantonsspital Frauenfeld- Urologische Klinik, Dept. of Urology, Frauenfeld, Switzerland, ²Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, ³University College London Hospital, Dept. of Urology, London, United Kingdom, ⁴Gent University Hospital, Dept. of Urology, Ghent, Belgium, ⁵Queen Mary Hospital, Dept. of Urology, Hong Kong, Hong Kong, ⁶La Paz University Hospital, Dept. of Urology, Madrid, Spain, ⁷CHIREC Cancer Institute, Dept. of Urology, Brussels, Belgium, ⁸Frimley Health, Dept. of Urology, London, United Kingdom, ⁹San Luigi Hospital, Dept. of Urology, Orbassano, Italy</p>
18:20 - 18:24	Pre-recorded lecture	<p>358 Litoxetine (LTX) shows significant treatment effect in urinary incontinence (UI)</p> <p>By: <u>Dmochowski R.</u></p> <p>Vanderbilt University Medical Center, Dept. of Urological Surgery, Nashville, United States of America</p>
18:24 - 18:28	Pre-recorded lecture	<p>364 Long-term outcomes from TVT procedures for treatment of female stress urinary incontinence: Data from a minimum of 18 years of follow-up</p> <p>By: <u>Song P.H.</u>, Kim Y.U. , Choi J.Y. , Ko Y.H. , Moon K.H. , Jung H.C.</p> <p>College of Medicine, Yeungnam University, Dept. of Urology, Daegu, South Korea</p>
18:28 - 18:32	Pre-recorded lecture	<p>363 Interim analysis of a European prospective observational study evaluating patient reported outcomes of Altis single incision sling in women operated for stress urinary incontinence</p> <p>By: <u>Capon G.</u>¹, Van Der Aa F.², Ryckebusch H.³, Ferry P.⁴</p> <p>¹Pellegrin hospital, Dept. of Urology, Bordeaux, France, ²UZ Leuven, Functional and reconstructive urology, neurourology, Leuven, Belgium, ³Coloplast, Medical Affairs Office, Le Plessis-Robinson, France, ⁴Saint Louis Hospital, Dept. of Gynaecology, La Rochelle, France</p>

18:32 - 18:36

Pre-recorded
lecture**1078 Complications after perineal surgery (with or without implantation of material):
First results of the French multicenter observatory VIGIMESH after 1873 inclusions**

By: Charles T.¹, Campagne-Loiseau S.², Cosson M.³, Ferry P.⁴, Saussine C.⁵, Lucot J.-P.⁶, Salet-Lizee D.⁷, Barussaud M.-L.⁸, Boisramé T.⁹, Carlier-Guérin C.¹⁰, Debodinance P.¹¹, Deffieux X.¹², Pizzoferrato A.-C.¹³, Curinier S.², Ragot S.¹⁴, Ringa V.¹⁵, De Tayrac R.¹⁶, Fauconnier A.¹⁷, Fritel X.¹⁸

¹CHU de Poitiers, Dept. of Urology, Poitiers, France, ²CHU Estaing, Dept. of Gynaecology and Obstetrics, Clermont-Ferrand, France, ³Université de Lille, Dept. of Gynaecology and Obstetrics, Lille, France, ⁴CH de La Rochelle, Dept. of Gynaecology and Obstetrics, La Rochelle, France, ⁵Université de Strasbourg, Dept. of Urology, Strasbourg, France, ⁶Hôpital Saint-Vincent-de-Paul, Dept. of Gynaecology and Obstetrics, Lille, France, ⁷Groupe Hospitalier Diaconesses-Croix-Saint-Simon, Dept. of Gynaecology, Paris, France, ⁸CHU de Poitiers, Dept. of Visceral Surgery, Poitiers, France, ⁹CHU de Strasbourg, Dept. of Gynaecology and Obstetrics, Strasbourg, France, ¹⁰CHU de Poitiers, Dept. of Gynaecology and Obstetrics, Poitiers, France, ¹¹CH de Dunkerque, Dept. of Gynaecology and Obstetrics, Dunkirk, France, ¹²Université Paris-Sud, Dept. of Gynaecology and Obstetrics, Paris, France, ¹³CHU de Caen, Dept. of Gynaecology and Obstetrics, Caen, France, ¹⁴Université de Poitiers, Clinical Investigation Center, Poitiers, France, ¹⁵Université de Poitiers, Inserm U1018, Poitiers, France, ¹⁶Université de Nîmes, Dept. of Gynaecology and Obstetrics, Nîmes, France, ¹⁷Université de Versailles Saint-Quentin-en-Yvelines, Dept. of Gynaecology and Obstetrics, Poissy, France, ¹⁸Université de Poitiers, Dept. of Gynaecology and Obstetrics, Poitiers, France

18:36 - 18:40

Pre-recorded
lecture**368 Robot-assisted artificial urinary sphincter implantation in female patients: An international multicenter study**

By: Peyronnet B.¹, Capon G.², Biardeau X.³, Belas O.⁴, Lecoanet P.⁵, Castro-Sader L.⁶, Allue M.⁶, Hein R.⁷, Daher M.⁸, Manunta A.¹, Robert G.², Hascoet J.¹, Dubois F.⁹, Thibault F.¹⁰, Cardot V.¹¹, Vidart A.¹², Descazeaud A.¹³, Fournier G.¹⁴, Everaerts W.¹⁵, Van Der Aa F.¹⁵

¹University of Rennes, Dept. of Urology, Rennes, France, ²University of Bordeaux, Dept. of Urology, Bordeaux, France, ³University of Lille, Dept. of Urology, Lille, France, ⁴Clinique Le Mans Sud, Dept. of Urology, Le Mans, France, ⁵University of Nancy, Dept. of Urology, Nancy, France, ⁶Vall Dhebron, Dept. of Urology, Barcelona, Spain, ⁷Magdeburg Klinik, Dept. of Urology, Magdeburg, Germany, ⁸Magdeburg University, Magdeburg, Germany, ⁹Clinique Saint-Gregoire, Dept. of Urology, Saint Grégoire, France, ¹⁰Metz Hospital, Dept. of Urology, Metz, France, ¹¹Clinique Bizet, Dept. of Urology, Paris, France, ¹²Foch Hospital, Dept. of Urology, Suresnes, France, ¹³University of Limoges, Dept. of Urology, Limoges, France, ¹⁴University of Brest, Dept. of Urology, Brest, France, ¹⁵University of Leuven, Dept. of Urology, Leuven, Belgium

Advanced reconstructive surgery

Video Session 3

**Wednesday 22
July
19:45 - 20:15****Location:** Virtual room 1**Chairs:** G. Al Edwan, Amman (JO)
A. Hosseini, Stockholm (SE)
F. Van Der Aa, Leuven (BE)

All videos have a maximum length of 8 minutes, followed by 4 minutes of live discussion.

19:45 - 19:49**V054 Technical aspects of Robotic Assisted Laparoscopic Ureterolysis (RALU) for the treatment of ureteric obstruction from Retroperitoneal Fibrosis (RPF)**By: Walsh A.L.W., Mc Dermott K. , La Rosa A. , Challacombe B. , O'brien T. , Fernando A.

Guy's and St. Thomas NHS Foundation Trust, Dept. of Urology, London, United Kingdom

19:49 - 20:01**V058 Double-face augmentation urethroplasty for bulbar urethral strictures-dorsal versus ventral approach: Technical implications and short-term outcomes**By: Enganti B., Chiruvella M. , Bendigeri M.T. , Ghouse S.M. , Ragoori D. , Reddy P.C. , Pandya S.

Asian Institute of Nephrology & Urology, Dept. of Urology, Hyderabad, India

Targeted treatment and personalised management of advanced bladder cancer

Poster Session 4

Thursday 23 July
18:00 - 18:45

Location: Virtual room 1

Chairs: M. De Santis, Berlin (DE)
F. Liedberg, Malmö (SE)
T. Seisen, Paris (FR)

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

18:00 - 18:04

Pre-recorded
lecture

1058 Cost-effectiveness analysis of the phase 3 IMvigor130 study evaluating atezolizumab as monotherapy or combined with platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic urothelial cancer

By: [Magee D.E.](#)¹, Cheung D.C.¹, Hird A.E.¹, Sridhar S.S.², Fallah-Rad N.², Fleshner N.E.³, Kulkarni G.K.³

¹University of Toronto, Dept. of Urology, Dept. of Surgery, Toronto, Canada, ²University of Toronto, Dept. of Medical Oncology, Department of Internal Medicine, University Health Network, Toronto, Canada, ³University of Toronto, Dept. of Urology, Dept. of Surgery, University Health Network, Toronto, Canada

18:04 - 18:08

Pre-recorded
lecture

1056 Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)

By: [Necchi A.](#)¹, Raggi D.¹, Bandini M.², Farè E.¹, Giannatempo P.¹, Colecchia M.¹, Pederzoli F.², Gallina A.², Marandino L.¹, Calareso G.¹, Madison R.³, Briganti A.², Ross J.³, Montorsi F.²

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³Foundation Medicine, Dept. of FMI, Cambridge, United States of America

18:08 - 18:12

Pre-recorded
lecture

768 Preliminary results of a European multicentre phase 1 study with Oncofid-P-B for the treatment of BCG unresponsive carcinoma in situ (CIS) of bladder at the end of 12 consecutive weeks intensive course and during ongoing monthly maintenance phase

By: [Hurle R.](#)¹, Guazzoni G.², Colombo P.³, Santoro A.⁴, De Cobelli O.⁵, Di Trapani E.⁵, Nohales G.⁶, Carlos L.⁷, Duran-Merino R.⁸, Lazzeri M.¹

¹IRCCS Humanitas Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, ²IRCCS Humanitas Clinical and Research Hospital - Humanitas University, Dept. of Urology, Rozzano, Italy, ³IRCCS Humanitas Clinical and Research Hospital, Dept. of Pathology, Rozzano, Italy, ⁴IRCCS Humanitas Clinical and Research Hospital - Humanitas University, Dept. of Oncology, Rozzano, Italy, ⁵IEO, Dept. of Urology, Milan, Italy, ⁶Hospital del Mar, Dept. of Urology, Barcelona, Spain, ⁷Hospital Universitario Fundacion Alcorcon, Dept. of Urology, Madrid, Spain, ⁸H.G.U., Dept. of Urology, Madrid, Spain

18:12 - 18:16	Pre-recorded lecture	<p>66 Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer</p> <p>By: <u>Necchi A.</u>¹, Raggi D.¹, Briganti A.², Farè E.¹, Giannatempo P.¹, Marandino L.¹, Gallina A.², Colecchia M.¹, Lucianò R.², Bianchi M.², Colombo R.², Salonia A.², Gandaglia G.², Fossati N.², Capitanio U.², Montorsi F.², Boormans J.³, Liu Y.⁴, De Jong J.³, Dittamore R.⁴, Davicioni E.⁴, Black P.⁵, Gibb E.⁴</p> <p>¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ⁴Decipher Biosciences, Decipher Biosciences, Vancouver, Canada, ⁵University of British Columbia, Dept. of Urology, Vancouver, Canada</p>
18:16 - 18:20	Pre-recorded lecture	<p>4 Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses</p> <p>By: <u>Pfister C.</u>¹, Gravis G.², Flechon A.³, Soulie M.⁴, Guy L.⁵, Laguerre B.⁶, Mottet N.⁷, Joly F.⁸, Allory Y.⁹, Harter V.¹⁰, Culine S.¹¹</p> <p>¹Rouen University Hospital, Dept. of Urology, Rouen, France, ²Paoli-Calmette Institute, Dept. of Oncology, Marseille, France, ³Leon Berard Cancer Center, Dept. of Oncology, Lyon, France, ⁴Rangueil University Hospital, Dept. of Urology, Toulouse, France, ⁵Clermont Ferrand University Hospital, Dept. of Urology, Clermont-Ferrand, France, ⁶Marquis Cancer Center, Dept. of Oncology, Rennes, France, ⁷Saint Etienne University Hospital, Dept. of Urology, Saint Etienne, France, ⁸Baclesse Cancer Center, Dept. of Oncology, Caen, France, ⁹Curie Cancer Institute, Dept. of Pathology, Paris, France, ¹⁰Baclesse Cancer Center, NW Canceropole Data Center, Caen, France, ¹¹Saint Louis University Hospital, Dept. of Oncology, Paris, France</p>
18:20 - 18:24	Pre-recorded lecture	<p>2 The supplementary GM-CSF to neoadjuvant gemcitabine-cisplatin systemic chemotherapy plus PD-L1 blockade decrease local tumor recurrence of urothelial carcinoma after surgery via suppression of MDSCs in blood and tumor microenvironment</p> <p>By: <u>Miyake M.</u>, Hori S., Nishimura N., Owari T., Itami Y., Nakai Y., Tanaka N., Fujimoto K.</p> <p>Nara Medical University, Dept. of Urology, Nara, Japan</p>
18:24 - 18:28	Pre-recorded lecture	<p>1 VAR2-armed CAR T-cells as an immunotherapeutic strategy for bladder cancer</p> <p>By: <u>Oo H.Z.</u>¹, Khazamipour N.¹, Ardekani G.¹, Roberts M.¹, Al Nakouzi N.¹, Gustavsson T.², Fazli L.¹, Salanti A.², Black P.¹, Daugaard M.¹</p> <p>¹Vancouver Prostate Centre, University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Centre for Medical Parasitology, University of Copenhagen, Dept. of Immunology and Microbiology, Copenhagen, Denmark</p>
18:28 - 18:32	Pre-recorded lecture	<p>908 The diagnostic accuracy of Bladder EpiCheck in high-risk population</p> <p>By: <u>Racioppi M.</u>¹, Di Gianfrancesco L.², Ragonese M.², Palermo G.², Sacco E.², Bassi P.F.²</p> <p>¹Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Dept. of Urology, Rome, Italy, ²Fondazione Policlinico Universitario, Dept. of Urology, Rome, Italy</p>

18:32 - 18:36

Pre-recorded
lecture**902 Xpert® bladder cancer monitor in the follow up of patients affected by non muscle invasive bladder cancer (NMIBC): An update**

By: D'Elia C.¹, Trenti E.¹, Folchini D.M.F.¹, Pycha S.², Mian C.³, Schwienbacher C.³, Hanspeter E.³, Pycha A.¹

¹Bolzano General Hospital, Dept. of Urology, Bolzano, Italy, ²Riga Stradins University, Dept. of Medicine, Riga, Latvia, ³Bolzano General Hospital, Dept. of Pathology, Bolzano, Italy

18:36 - 18:40

Pre-recorded
lecture**901 Evaluation of ADXBLADDER and cytology performance in the follow up of NMIBC: A blinded prospective multicentric study**

By: Gontero P.¹, Montanari E.², Roupret M.³, Longo F.², Stockley J.⁴, Kennedy A.⁴, Rodríguez Ó.⁵, Sieverink C.⁶, Vanié F.⁷, Allasia M.¹, Witjes J.A.⁶, Colombel M.⁸, Sylvester R.⁹, McCracken S.¹⁰, Dudderidge T.¹¹, Palou J.⁵

¹Ospedale Molinette, Dept. of Urology, Turin, Italy, ²Universita' Policlinico Milano, Dept. of Urology, Milan, Italy, ³Hôpital Pitié-Salpêtrière, Sorbonne University, Dept. of Urology, Paris, France, ⁴Arquer Diagnostics, Dept. of R&D, Sunderland, United Kingdom, ⁵Fundacio Puigvert, Dept. of Urology, Barcelona, Spain, ⁶Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ⁷Hôpital Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁸Hôpital Edouard Herriot, Dept. of Urology, Lyon, France, ⁹EAU Non-muscle Invasive Guidelines Panel, EAU Guidelines Office, Brussels, Belgium, ¹⁰Sunderland Royal Hospital, Dept. of Urology, Sunderland, United Kingdom, ¹¹University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom

Improving outcomes in the treatment of bladder cancer

Video Session 4

**Thursday 23 July
19:45 - 20:15****Location:** Virtual room 1**Chairs:** J.W. Collins, London (GB)
K. Decaestecker, Ghent (BE)
O. Traxer, Paris (FR)

All videos have a maximum length of 8 minutes, followed by 4 minutes of live discussion.

19:45 - 19:55**V057 Safety and short-term oncological outcomes of thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer: A prospective non-randomized phase II trial**By: Enikeev D.¹, Taratkin M.¹, Laukhtina E.¹, Sukhanov R.¹, Dymov A.¹, Sorokin N.², Shariat S.F.³, Glybochko P.¹¹Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia,²Moscow State University, Dept. of Urology, Moscow, Russia, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria**19:55 - 20:06****V028 Sex-sparing robot-assisted radical cystectomy with intracorporeal Padua ileal neobladder in female: Surgical technique, perioperative, oncologic and functional outcomes**By: Tuderti G., Mastroianni R., Flammia S., Ferriero M., Leonardo C., Anceschi U., Brassetti A., Guaglianone S., Gallucci M., Simone G.

Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

Renal Cell Carcinoma

Poster Session 5

Friday 24 July
18:00 - 18:45**Location:** Virtual room 1**Chairs:** R. Boissier, Marseille (FR)
B.J. Challacombe, London (GB)
A. Minervini, Florence (IT)

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

18:00 - 18:04

Pre-recorded
lecture**601 The impact of delay in time to surgery on outcomes of localized renal cell carcinoma: Analysis based on tumor size**By: Patel D. , Ghali F , Meagher M. , Bradshaw A. , Patel S. , Dutt R. , Miller N. , Keiner C. , Cotta B. , Murphy J. , Derweesh I.

University of California San Diego, Dept. of Urology, San Diego, United States of America

18:04 - 18:08

Pre-recorded
lecture**33 The impact of 3D digital reconstruction on the surgical planning of partial nephrectomy: A prospective case-control trial**By: Schiavina R. ¹, Bianchi L. ¹, Barbaresi U. ¹, Chessa F. ¹, Angiolini A. ¹, Mineo Bianchi F. ¹, Molinaroli E. ¹, Bortolani B. ², Cercenelli L. ², Marcelli E. ², Brunocilla E. ¹
¹Sant'orsola-Malpighi Hospital, University of Bologna, Dept. of Urology, Bologna, Italy,
²University of Bologna, Dept. of Experimental, Diagnostic and Specialty Medicine (DIMES), Laboratory of Bioengineering, Bologna, Italy

18:08 - 18:12

Pre-recorded
lecture**469 Novel classification model of tumour shape irregularity: Significance for predicting potential oncologic risks in clinically localised renal cell carcinoma**By: Tanaka H. ¹, Shimada W. ¹, Fukuda S. ¹, Fukushima H. ¹, Moriyama S. ¹, Uehara S. ¹, Kijima T. ¹, Yoshida S. ¹, Yokoyama M. ¹, Ishioka J. ¹, Matsuoka Y. ¹, Saito K. ¹, Campbell S. ², Fujii Y. ¹¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Cleveland Clinic, Dept. of Glickman Urological and Kidney, Cleveland, United States of America

18:12 - 18:16

Pre-recorded
lecture**30 The IRON study: Investigation of Robot-assisted versus Open Nephron-sparing surgery**By: Larcher A. ¹, Rosiello G. ¹, Minervini A. ², Mari A. ², Di Maida F. ², Bensalah K. ³, Peyronnet B. ³, Khene Z. ³, Schiavina R. ⁴, Bianchi L. ⁴, Mottrie A. ⁵, De Naeyer G. ⁵, Mazzone E. ⁵, Antonelli A. ⁶, Furlan M. ⁷, Rha K.H. ⁸, Almujaalhem A. ⁸, Derweesh I. ⁹, Bradshaw A. ⁹, Kaouk J. ¹⁰, Sawczyn G. ¹⁰, Bertolo R. ¹⁰, Montorsi F. ¹, Capitanio U. ¹¹Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Dept. of Experimental Oncology, Milan, Italy,
²Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, ³University of Rennes, Dept. of Urology, Rennes, France, ⁴S. Orsola-Malpighi Hospital, University of Bologna, Dept. of Urology, Bologna, Italy, ⁵Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, ⁶Azienda Ospedaliera Universitaria Integrata, University of Verona, Dept. of Urology, Verona, Italy, ⁷Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, ⁸Yonsei University College of Medicine, Urological Science Institute, Seoul, South Korea, ⁹Moore's UCSD Cancer Center, University of California San Diego School of Medicine, Dept. of Urology, San Diego, United States of America, ¹⁰Glickman Urological and Kidney Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America

18:16 - 18:20

Pre-recorded
lecture**597 Renal biopsies performed before or during ablation: A comparison of different diagnostic strategies in small renal cell tumors**

By: Widdershoven C.V.¹, Aarts B.M.², Zondervan P.J.¹, Van Delden O.M.³, Klompenhouwer E.G.², Prevoo W.⁴, Montauban Van Swijndregt A.D.⁵, Henderickx M.M.E.L.¹, Van Moorselaar R.J.A.¹, Bex A.⁶, Lagerveld B.W.⁵

¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Antoni van Leeuwenhoek, Dept. of Radiology, Amsterdam, The Netherlands, ³Amsterdam UMC, Dept. of Radiology, Amsterdam, The Netherlands, ⁴Onze Lieve Vrouwe Gasthuis, Dept. of Radiology, Amsterdam, The Netherlands, ⁵Onze Lieve Vrouwe Gasthuis, Dept. of Urology, Amsterdam, The Netherlands, ⁶Antoni van Leeuwenhoek, Dept. of Urology, Amsterdam, The Netherlands

18:20 - 18:24

Pre-recorded
lecture**603 Benchmarking current nephrectomy practice in malignant disease in England: An analysis of the BAUS complex operation registry**

By: Pascoe J.M.¹, John J.B.¹, Fowler S.², Narahari K.³, Challacombe B.⁴, Mcgrath J.S.¹

¹Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, ²British Association Of Urologists, Dept. of Urology, London, United Kingdom, ³University Hospital of Wales, Dept. of Urology, Cardiff, United Kingdom, ⁴Guy's and St Thomas' Hospitals, Dept. of Urology, London, United Kingdom

18:24 - 18:28

Pre-recorded
lecture**834 Nephrectomy after complete response to immune checkpoint inhibitors for metastatic Renal Cell Carcinoma (mRCC): A new surgical challenge?**

By: Pignot G.¹, Thiery-Vuillemin A.², Walz J.¹, Lang H.³, Werle P.³, Balssa L.⁴, Geoffrois L.⁵, Leblanc L.⁶, Albigès L.⁷, Di Nunno V.⁷, Bensalah K.⁸, Ladoire S.⁹, Gravis G.¹⁰, Barthélémy P.¹¹

¹Institut Paoli-Calmettes, Dept. of Surgical Oncology 2, Marseille, France, ²CHRU Besançon, Hopital Jean Minjoz, Dept. of Medical Oncology, Besançon, France, ³University hospital of Strasbourg, Dept. of Urology, Strasbourg, France, ⁴CHRU Besançon, Hopital Jean Minjoz, Dept. of Urology, Besançon, France, ⁵Institut de cancérologie de Lorraine, Dept. of medical oncology, Vandoeuvre lès Nancy, France, ⁶CHRU Nancy, Hôpitaux de Brabois, Dept. of Urology, Vandoeuvre lès Nancy, France, ⁷Institut Gustave Roussy, Dept. of medical oncology, Villejuif, France, ⁸CHU Rennes, Hopital Pontchaillou, Dept. of Urology, Rennes, France, ⁹Centre Georges-François Leclerc, Dept. of medical oncology, Dijon, France, ¹⁰Institut Paoli-Calmettes, Dept. of Medical Oncology, Marseille, France, ¹¹University hospital of Strasbourg, Dept. of Medical Oncology, Strasbourg, France

18:28 - 18:32

Pre-recorded
lecture**835 Variations in the exposure to sunitinib with immediate and deferred cytoreductive nephrectomy (CN). A post-hoc analysis of the randomized controlled EORTC SURTIME trial**

By: Abu-Ghanem Y.¹, Van Thienen H.², Blank C.², Powles T.³, Collette L.⁴, Tombal B.⁵, Haanen J.², Bex A.⁶

¹Sheba Medical Centre, Dept. of Urology, Ramat-Gan, Israel, ²The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, ³Barts Cancer Centre, Dept. of Oncology, London, United Kingdom, ⁴EORTC, Statistics, Brussels, Belgium, ⁵Catholic University Louvain, Dept. of Urology, Brussels, Belgium, ⁶The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

18:32 - 18:36

Pre-recorded
lecture**846 Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry**

By: Meagher M.F. ¹, Mir M. ², Rubio J. ², Campi R. ³, Minervini A. ³, Kriegmair M. ⁴, Heck M. ⁵, Van Bruwaene S. ⁶, Linares E. ⁷, Hevia V. ⁸, Musquera M. ⁹, D'anna M. ⁹, Ghali F. ¹, Patel D. ¹, Bradshaw A. ¹, Autorino R. ¹⁰, Guruli G. ¹⁰, Rousel E. ¹¹, Albertsen M. ¹¹, Pavan N. ¹², Claps F. ¹², Antonelli A. ¹³, Palumbo C. ¹³, Marchioni M. ¹⁴, Derweesh I. ¹

¹University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ²Fundacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain, ³University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ⁴University Medical Centre Mannheim, Dept. of Urology, Mannheim, Germany, ⁵Technical University of Munich, Dept. of Urology, Munich, Germany, ⁶AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, ⁷Hospital La Paz, Dept. of Urology, Madrid, Spain, ⁸Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain, ⁹Hospital Clinic, Dept. of Urology, Barcelona, Spain, ¹⁰VCU Medical Center, Dept. of Urology, Richmond, United States of America, ¹¹UKLeuven, Dept. of Urology, Leuven, Belgium, ¹²University of Trieste, Dept. of Medical, Surgical and Health Science, Trieste, Italy, ¹³Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, ¹⁴University of Chieti, Dept. of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, Chieti, Italy

18:36 - 18:40

Pre-recorded
lecture**PT183 Recommendations for follow up of surgically resected chromophobe renal cell carcinoma**

By: Vanaclocha Saiz L. ¹, Neves J.B. ¹, Marchetti M. ², Barod R. ², Patki P. ², Mumtaz F. ², Dabestani S. ³, Tran M.G.B. ¹, Bex A. ²

¹University College London, Division of Surgery and Interventional Science, London, United Kingdom, ²Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer, London, United Kingdom, ³Lund University, Dept. Clinical Sciences, Lund, Lund, Sweden

Emerging technologies in partial nephrectomy

Video Session 5

Friday 24 July
19:45 - 20:15

Location: Virtual room 1

Chairs: A. Mottrie, Melle (BE)
M. Musquera Felip, Barcelona (ES)
P-T. Piéchaud, Bordeaux (FR)

All videos have a maximum length of 8 minutes, followed by 4 minutes of live discussion.

19:45 - 19:57

V059 Innovations and technical variations in robot-assisted kidney transplantation: Results from the ERUS working group

By: Gallioli A.¹, Boissier R.¹, Territo A.¹, Campi R.², Vignolini G.², Musquera M.³, Alcaraz A.³, Decaestecker K.⁴, Tugcu V.⁵, Vanacore D.¹, Serni S.², Breda A.¹

¹Fundacio Puigvert, Dept. of Urology, Barcelona, Spain, ²Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, ³Hospital Clinic, Dept. of Urology, Barcelona, Spain, ⁴Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁵Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Dept. of Urology, Istanbul, Turkey

19:57 - 20:09

V001 Beyond the limits of ultrasound: Three dimensional augmented reality robot assisted partial nephrectomy (3D AR-RAPN) for complex renal masses

By: Porpiglia F.¹, Checcucci E.¹, Amparore D.¹, Piramide F.¹, Volpi G.¹, De Cillis S.¹, Verri P.¹, Manfredi M.¹, Piazzolla P.², Fiori C.¹, Vezzetti E.², Mottrie A.³

¹AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ²Politecnico di Torino, Dept. of Management and Production Engineering, Turin, Italy, ³OLV Hospital, Dept. of Urology, Aalst, Belgium

Management of prostate cancers – from screening to metastasis

Poster Session 6

Saturday 25 July
18:00 - 18:45

Location: Virtual room 1

Chairs: Z. Culig, Innsbruck (AT)
G.P. Haas, Syracuse (US)

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

18:00 - 18:04

Pre-recorded
lecture

51 From screening to mortality reduction: An overview of the patient journey in ERSPC Rotterdam

By: Roobol M.J., Remmers S. , Van Slooten-Midderigh M.E. , Franken-Raab C.G.A.M. Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands

18:04 - 18:08

Pre-recorded
lecture

PT145 Long-term oncological outcomes following active surveillance of low risk prostate cancer: A population-based study

By: Timilshina N.¹, Finelli A.¹, Richard P.¹, Komisarenko M.¹, Martin .L.¹, Tomlinson G.², Sander B.², Alibhai S.³

¹Univeristy Health Network, Dept. of Surgical Oncology, Toronto, Canada, ²Univeristy Health Network, Toronto Health Economics and Technology Assessment (THETA), Toronto, Canada, ³Univeristy Health Network, Dept. of Medicine, Toronto, Canada

18:08 - 18:12

Pre-recorded
lecture

PT157 Association of Mediterranean diet score and disease progression among localized prostate cancer patients on active surveillance

By: Gregg J.¹, Zhang X.², Zheng J.², Ward J.F.¹, Kim J.³, Davis J.W.¹, Daniel C.²

¹UT MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ²UT MD Anderson Cancer Center, Dept. of Epidemiology, Houston, United States of America, ³Merck & Co., Dept. of Clinical Research, Kenilworth, United States of America

18:12 - 18:16

Pre-recorded
lecture

PT151 Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer

By: Loneragan P.E., Washington S.L. , Zhao S. , Cowan J.E. , Nguyen H.G. , Shinohara K. , Cooperberg M.R. , Carroll P.R.

University of California, Dept. of Urology, San Francisco, CA, United States of America

18:16 - 18:20

Pre-recorded
lecture

PT418 Prostate mapping for cancer diagnosis: The Madrid protocol. Transperineal prostate biopsies combining micro-ultrasound and mpMRI fusion biopsy

By: Rodríguez Socarrás M.E., Gomez Rivas J.A. , Cuadros V. , Reinoso Elbers J. , Llanes Gonzalez L. , Juarez Del Dago P. , Fernandez Del Alamo J. , Michel Mercado I.E. , Gomez Sancha F.

Instituto de Cirugía Urológica Avanzada (ICUA), Dept. of Urology, Madrid, Spain

18:20 - 18:24

Pre-recorded
lecture

PT053 Impact of residual microscopical evidence of prostate cancer at second tumor resection on biochemical recurrence after radical prostatectomy

By: Tully K.H.¹, Schulmeyer M.¹, Reike M.¹, Hanske J.¹, Von Landenberg N.¹, Moritz R.¹, Brock M.¹, Hendrik J.², Von Bodman C.¹, Noldus J.¹, Palisaar R.¹, Roghmann F.¹

¹Marien Hospital Herne, Ruhr University Bochum, Dept. of Urology and NeuroUrology, Herne, Germany, ²Ruhr University Bochum, Institute of Pathology, Herne, Germany

18:24 - 18:28	Pre-recorded lecture	<p>1110 Patient-reported outcomes of neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial – a phase II trial</p> <p>By: <u>Yang X.Y.</u>, Aslim E.J. , Chong T.W. , Yuen J.S.P. , Tay K.J. , Ho H.S.S. , Lee L.S. Singapore General Hospital, Dept. of Urology, Singapore, Singapore</p>
18:28 - 18:32	Pre-recorded lecture	<p>692 Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series</p> <p>By: <u>Fossati N.</u>¹, Karnes R.J.², Boorjian S.A.², Motterle G.², Bossi A.³, Kumar T.³, Di Muzio N.⁴, Cozzarini C.⁴, Noris Chiorda B.⁴, Mazzone E.⁵, Gandaglia G.¹, Barletta F.¹, Scuderi S.¹, Robesti D.¹, Bartkowiak D.⁶, Shariat S.⁷, Goldner G.⁸, Devos G.⁹, Joniau S.⁹, Berghen C.¹⁰, De Meerleer G.¹⁰, Van Poppel H.⁹, Montorsi F.¹, Wiegel T.⁶, Briganti A.¹</p> <p>¹IRCCS Ospedale San Raffaele, Dept. of Oncology, Unit of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵IRCCS Ospedale San Raffaele, Dept. of Oncology, Unit of Urology, Milan, Italy, ⁶University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁸Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium</p>
18:32 - 18:36	Pre-recorded lecture	<p>1044 Longitudinal analysis of personal DNA methylome patterns in metastatic prostate cancer</p> <p>By: Silva R.S.¹, Moran B.M.², Gallagher W.G.³, Brennan D.B.², <u>Perry A.</u>¹</p> <p>¹University College Dublin, Dept. of Biology and Environmental Science, Dublin, Ireland, ²University College Dublin, Dept. of Medicine, Dublin, Ireland, ³University College Dublin, Dept. of Biomolecular and Biomedical Science, Dublin, Ireland</p>
18:36 - 18:40	Pre-recorded lecture	<p>PT090 Inhibition steroid sulfatase suppresses androgen signaling and improves response to enzalutamide</p> <p>By: <u>Gao A.</u>¹, Armstrong M.¹, Liu C.¹, Liu L.², Yang J.¹, Lou W.¹, Li P.³, Evans C.¹</p> <p>¹University of California Davis, Dept. of Urology, Sacramento, United States of America, ²Sichuan University, Dept. of Urology, Chengdu, China, ³Ohio State University, Pharmacy, Columbus, United States of America</p>

Advances in the treatment of localised prostate cancer

Video Session 6

Saturday 25 July
19:45 - 20:15**Location:** Virtual room 1**Chairs:** W.L.M. Everaerts, Leuven (BE)
F. Gómez Veiga, Salamanca (ES)
S. Nathan, London (GB)

All videos have a maximum length of 8 minutes, followed by 4 minutes of live discussion.

19:45 - 19:54**V053 3D augmented reality robot-assisted radical prostatectomy: The computer vision algorithm allows to identify the extracapsular extension on neurovascular bundles**By: Porpiglia F.¹, Checcucci E.¹, Amparore D.¹, Piana A.¹, Piramide F.¹, Volpi G.¹, De Cillis S.¹, Manfredi M.¹, Piazzolla P.², Fiori C.¹, Vezzetti E.²¹AOU San Luigi Gonzaga, University of Turin, Dept. of Urology, Orbassano, Italy,²Politecnico di Torino, Dept. of Management and Production Engineering, Turin, Italy**19:54 - 20:06****V023 Evaluation of pain in office based transperineal targeted prostate biopsy under local anesthesia using a modified anesthetic protocol**By: Messas A., Vienney N., Beley S., Dumonceau O., Dominique S., Peyrat L., Alechinsky L., Benbouzid S., Haab F.

American Hospital of Paris, Dept. of Urology, Paris, France

The top 10% - News on stones

Poster Session 7

Sunday 26 July
18:00 - 18:45**Location:** Virtual room 1**Chairs:** T.R.W. Herrmann, Frauenfeld (CH)
P. Krombach, Luxembourg (LU)
B. Somani, Southampton (GB)

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

18:00 - 18:04Pre-recorded
lecture**785 Wisconsin quality of life machine learning algorithm for predicting quality of life in kidney stone patients**By: Nguyen D-D.¹, Luo J.W.¹, Lim J.R.Z.², Scotland K.B.², Bechis S.K.³, Sur R.L.³, Nakada S.Y.⁴, Antonelli J.A.⁵, Streeper N.M.⁶, Sivalingam S.⁷, Viprakasit D.P.⁸, Averch T.D.⁹, Landman J.¹⁰, Chi T.¹¹, Pais, Jr. V.M.¹², Bird V.G.¹³, Andonian S.¹⁴, Canvasser N.E.¹⁵, Harper J.D.¹⁶, Chew B.H.², Penniston K.L.⁴, Bhojani N.¹⁷¹McGill University, Faculty of Medicine, Montreal, Canada, ²University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ³University of California San Diego School of Medicine, Dept. of Urology, San Diego, United States of America, ⁴University of Wisconsin-Madison, Dept. of Urology, Madison, United States of America, ⁵University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁶Pennsylvania State University College of Medicine, Dept. of Urology, Hershey, United States of America, ⁷Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, United States of America, ⁸University of North Carolina School of Medicine, Dept. of Urology, Chapel Hill, United States of America, ⁹Palmetto Health USC Medical Group, Dept. of Urology, Columbia, United States of America, ¹⁰University of California Irvine School of Medicine, Dept. of Urology, Orange, United States of America, ¹¹University of California San Francisco School of Medicine, Dept. of Urology, San Francisco, United States of America, ¹²Dartmouth Hitchcock Medical Center, Dept. of Urology, Lebanon, United States of America, ¹³University of Florida College of Medicine, Dept. of Urology, Gainesville, United States of America, ¹⁴McGill University Health Center, Dept. of Urology, Montreal, Canada, ¹⁵University of California Davis School of Medicine, Dept. of Urology, Sacramento, United States of America, ¹⁶University of Washington, Dept. of Urology, Seattle, United States of America, ¹⁷Université de Montréal, Dept. of Urology, Montreal, Canada

18:04 - 18:08	Pre-recorded lecture	<p>789 Development of a risk calculator to predict spontaneous stone passage in patients with acute ureteric colic</p> <p>By: <u>Gao C.</u>¹, Peters M.², Jayaraajan K.¹, Todd M.³, Cashman S.¹, Nambiar A.¹, Cumberbatch M.⁴, Lamb B.¹, Peacock A.⁵, Van Son M.J.², Van Rossum P.S.N.², Pickard R.⁶, Erotocritou P.⁷, Smith D.⁸, Kasivisvanathan V.¹, Shah T.¹</p> <p>¹British Urology Researchers in Surgical Training (BURST), London, United Kingdom, ²University Medical Center Utrecht, Cancer Center, Dept. of Radiation Oncology, Utrecht, The Netherlands, ³Australian Young Urology Researchers Organisation (YURO), Heidelberg, Victoria, Australia, ⁴University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, ⁵University College London (UCL), Information Services Division, London, United Kingdom, ⁶Newcastle University, Dept. of Urology, Newcastle, United Kingdom, ⁷Whittington Hospital, Dept. of Urology, London, United Kingdom, ⁸UCL Hospital, Dept. of Urology, London, United Kingdom</p>
18:08 - 18:12	Pre-recorded lecture	<p>546 Cost-efficiency analysis of reusable versus single-use flexible ureteroscopy and the development of a formula to evolve to a cost-efficient hybrid model</p> <p>By: <u>Van Compernelle D.</u>, Veys R., Beysens M., Van Haute C., Taily T.</p> <p>Ghent University Hospital, Dept. of Urology, Ghent, Belgium</p>
18:12 - 18:16	Pre-recorded lecture	<p>548 The risk of unplanned healthcare utilization in patients undergoing ureteroscopy with uncorrected bleeding diathesis in a surgical collaborative</p> <p>By: Hiller S.C.¹, Swarna K.¹, Leavitt D.², Frontera J.R.³, Jafri S.M.⁴, Hollingsworth J.¹, Dauw C.¹, <u>Ghani K.</u>¹, For The Michigan Urological Surgery Improvement Collaborative.¹</p> <p>¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ³Michigan Institute of Urology, Dept. of Urology, Rochester, United States of America, ⁴William Beaumont Hospital, Dept. of Urology, Royal Oak, United States of America</p>
18:16 - 18:20	Pre-recorded lecture	<p>PT115 Antegrade flexible nephroscopy (second-look) in gas (CO2) medium: New technique for residual stones removal</p> <p>By: <u>Korolev D.</u>, Rapoport L., Tsarichenko D., Enikeev M., Taratkin M., Enikeev D., Glybochko P.</p> <p>Sechenov University, Dept. of Urology and Reproductive Health, Moscow, Russia</p>
18:20 - 18:24	Pre-recorded lecture	<p>666 The first prospective assessment of S.T.O.N.E, Guy, CROES, S-ReSC nomograms in the prediction of percutaneous nephrolithotomy outcomes</p> <p>By: <u>Elkaramany T.</u>, Al Adl A., Mohey A., Abedel Aal A., Abu Elnasr H., Noureldin Y.</p> <p>Faculty of Medicine, Benha University, Dept. of Urology, Benha, Egypt</p>
18:24 - 18:28	Pre-recorded lecture	<p>670 Super-mini PCNL (SMP) vs. standard PCNL for the management of renal calculi <2 cm: A randomized controlled study</p> <p>By: Chawla A.K., Gudetti R., Kapadia A., <u>Hegde P.</u>, Bin Mohammed Z., Mohan A.</p> <p>KMC Manipal, MAHE, Dept. of Urology and Renal Transplant, Manipal, India</p>
18:28 - 18:32	Pre-recorded lecture	<p>182 The effect of alternating bidirectional approach during shock wave lithotripsy for upper lumbar ureteric stones. A randomized controlled trial</p> <p>By: Hegazy M.¹, El-Assmy A.¹, Ali-El-Dein B.¹, Lashin A.M.¹, <u>Attya M.</u>², Elbaz R.¹, Sheir K.¹</p> <p>¹Mansoura Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt, ²UNC, Dept. of Urology, Mansoura, Egypt</p>

18:32 - 18:36

Pre-recorded
lecture**176 Pulse modulation with Moses technology improves popcorn laser lithotripsy**By: Black K.M. ¹, Aldoukhi A.H. ¹, Teichman J. ², Hall T. ³, Roberts W. ¹, Ghani K. ¹¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America,²University of British Columbia, Vancouver, Dept. of Urologic Sciences, Vancouver,Canada, ³University of Michigan, Dept. of Engineering, Ann Arbor, United States of America

18:36 - 18:40

Pre-recorded
lecture**PT131 In vitro comparison of ablation rates between superpulsed thulium fiber laser and ho:Yag laser for endocorporeal lithotripsy**By: Panthier F. ¹, Doizi S. ¹, Berthe L. ², Traxer O. ¹¹Hopital Tenon, Dept. of Urology, Paris, France, ²Ecole Supérieure des Arts et Métiers,

PIMM Laboratory, Paris, France

3D guidance for stone management

Video Session 7

Sunday 26 July
19:45 - 20:15

Location: Virtual room 1

Chairs: J-T. Klein, Ulm (DE)
M. Lezrek, Meknes (MA)
A. Skolarikos, Athens (GR)

All videos have a maximum length of 8 minutes, followed by 4 minutes of live discussion.

19:45 - 19:51

V008 The mobile app displaying inside view of the kidney's PCS and measuring infundibulopelvic angle. Is there any difference with the existing methods?

By: Guliev B. , Komyakov B. , [Talyshinskii A.](#)

North-Western State Medical University named after I.I.Mechnikov, Dept. of Urology, Saint Petersburg, Russia

19:51 - 20:03

V010 3D mixed reality guidance for percutaneous puncture during kidney stones surgical treatment

By: [Porpiglia F.](#), Checcucci E. , Amparore D. , Peretti D. , Piramide F. , De Cillis S. , Verri P. , Niculescu Razvan G. , Poggio M. , Cossu M. , Fiori C.

AOU San Luigi Gonzaga, University of Turin, Dept. of Urology, Orbassano, Italy

